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ABSTRACT 
 
BRYAN TIMOTHY RICHARDSON:  Defining the molecular mechanisms of the 
Cerebral Cavernous Malformation proteins. 
(Under the Direction of Gary L. Johnson, Ph.D.) 
 
Cerebral cavernous malformations (CCM) are the second most common 
class of cerebrovascular brain malformations affecting .1-.5% of the population.  The 
disease is manifested in endothelial cells as lesions of thin, dilated, and leaky 
capillaries lacking normal blood vessel-stromal interactions.  Lesions cause varied 
symptoms ranging from minor headaches to seizure and hemorrhagic stroke.  CCMs 
can be incurred sporadically or inherited in an autosomal dominant manner from loss 
of function mutations in one of three genes, ccm1/krit1, ccm2/osm, or ccm3/pdcd10.  
These mutations affect the actin cytoskeleton due to deregulated RhoA/ROCK 
signaling, which increases stress fiber incidence, reduces endothelial cell barrier 
function, and decreases angiogenesis in vitro.  We demonstrate through global 
kinome profiling that numerous kinases controlling the actin cytoskeleton are 
deregulated.  Of these, we demonstrate that the RhoA/ROCK effector LIM kinase is 
overactive and phosphorylates and in activates the actin depolymerizing factor cofilin.  
Importantly, in vitro CCM phenotypes are rescued with knock down of LIM kinase in 
CCM protein deficient cells.  We further show that a potential molecular mechanism 
governing the elevated RhoA levels and activity is through the E3 ubiquitin ligase 
	   iii	  
Smurf1, which associates with CCM2 but not CCM1 or CCM3 and is responsible for 
ubiquitinating GTP bound RhoA.  Current cell culture and animal models of CCM 
have given insight into CCM phenotypes, but the study of patient cells are needed to 
validate these models and to test potential therapeutics.  Thus, we provide proof of 
principle studies demonstrating the utility of both endothelial progenitor derived 
endothelial cells and pluripotent stem cells in CCM disease modeling for the ultimate 
goal of producing a library of patient induced pluripotent stem cells.  Overall, our 
findings elaborate on and provide insight into the complex molecular pathways 
involved in CCM phenotypes while also making the first steps towards in vitro patient 
specific CCM disease modeling.    
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I. Introduction 
  
CCM prevalence and pathophysiology  
Stroke is a leading cause of death in the United States behind heart disease 
and cancer.  Cerebral cavernous malformation (CCM; OMIM 116860) is the second 
most prevalent intracranial vascular malformation (IVM), which has symptoms 
ranging from mild headaches to epileptic seizure to hemorrhagic stroke [1].  Lesions 
appear principally in the central nervous system vasculature, but there have been 
reports of peripheral lesions in the retina, liver, and spinal cord [2].  Pathologically, 
CCM lesions are clusters of leaky capillaries, and the only treatment option for CCM 
is through invasive surgery or radiation therapy.  Recent in vitro and in vivo 
experiments have attributed lesion generation to a break down of normal vascular 
remodeling and the blood brain barrier (BBB) linked to deregulation of the actin 
cytoskeleton of endothelial cells (EC)s through aberrantly high levels of the small 
GTPase RhoA [3-8].   
 
CCM	  inheritance	  	  
CCM can be inherited in an autosomal dominant fashion or incurred 
sporadically [9]. In nearly all cases, loss of function gene mutations that lead to non-
sense mediated mRNA decay have been mapped to three genes, krit1 (ccm1), osm 
(ccm2), or pdcd10 (ccm3). CCMs are found in .4-.8% of the population with a higher 
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prevalence in Hispanic populations due to the presence of a founder mutation [10-
12]. Mutation rates of the three genes have been estimated at 40%, 20%, and 40% 
for CCM1, CCM2, and CCM3, respectively [13-16].  Both genders are affected 
equally, and lesions are detected at a mean age of 35 with 25% of the cases 
presenting in childhood [17-19].  However, broad ranges, 10-40% of patients with 
CCM lesions remain asymptomatic [1, 20].  CCM symptom severity is a function of 
lesion location, size, and likelihood of hemorrhage [21].  CCM disease occurs 
sporadically and familially in an inherited form with 10-40% and over 50% in the 
Caucasian and Hispanic populations, respectively [2, 9].  There is some debate on 
the prevalence of familial CCM lesions as a study determined that 75% of reported 
sporadic CCMs were actually familial [22].  These numbers are skewed to more 
sporadic reporting of CCM lesions because CCM patients typically aren’t genetically 
tested for germ-line mutations and typically do not receive genetic counseling.  
Interestingly, 22% of CCM patients that have multiple lesions have no mutation in 
any of the CCM genes, suggesting that other deregulated genes may cause CCM 
lesions to form [23].  This finding may also result from inadequate older generation 
PCR gene mutation identification strategies, which do not identify potential point 
mutations that can inhibit CCM gene function without complete protein loss.  The 
identification of familial patients is important with over 50% of familial patients 
accruing multiple lesions, which are larger and more severe.  In contrast, only 12% 
of sporadic patients have multiple lesions [1, 24].  Early lesion identification allows 
for the careful MRI monitoring of CCM lesions, which improves morbidity.  Thus, 
recent advances in deep sequencing technology will make CCM patient gene 
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mutation identification more commonplace and accurate, which will expand current 
knowledge of familial vs. sporadic CCM formation and which CCM gene is mutated.   
 
CCM pathophysiology 
CCMs are characterized as well-circumscribed lesions that have a mulberry-
like appearance ranging in size from one millimeter up to nine centimeters [25, 26]. 
Most all of CCM lesions are located within the subcortical cerebrum [27, 28].  
Histologically, the endothelium has thin dilated walls with an intact basal lamina 
lacking any intervening brain parenchyma often with signs of prior 
microhemorrhages and hemosiderin deposition [25, 29, 30].  Typically, lesions have 
clots of blood in the endothelial lumen [30].  Endothelial cells maintain contacts with 
pericytes and astrocytes for the establishment of the blood brain barrier (BBB).  
However, CCM protein deficient ECs are void of these intracellular contacts, which 
decreases BBB stability and increases vascular leak [30].  Lesions are stratified into 
two stages; stage 1 lesions have enlarged blood vessels with hemosiderin deposits, 
and stage 2 lesions have more clusters of tangled blood vessels with calcification 
and astrogliosis [31].  Lesions increase both in size and severity with age, and they 
principally occur in areas of de-novo angiogenesis following surgical intervention [2, 
32, 33]. 
CCM lesions are diagnosed through MRI as multi-lobule structures with a 
peripheral hemosiderin ring and are monitored yearly; they are observed until 
symptoms require treatment.  Epilepsy and seizure symptoms are pharmacologically 
treated; however, numerous side effects occur, and up to 50% of CCM patients do 
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not respond to anti-epileptics [34].  In these cases, surgery is recommended, but 
many CCM lesions are surgically inaccessible.  Radiation surgery is an alternative, 
but this method has increased complication rates with 16% of patients displaying 
permanent neurological deficits [35, 36].  These facts highlight the importance of 
understanding the basic signaling mechanisms contributing to CCM, which will 
promote the generation of non-invasive pharmacological agents for the treatment of 
CCM. 
 
Knudson	  two	  hit	  hypothesis	  of	  loss	  of	  heterozygosity. 
Specific inactivation of the mutated CCM protein in endothelial cells from 
patient lesion samples but not in surrounding normal brain tissue has given rise to 
the notion of CCM as a disease defined by a loss of heterozygosity, similar to the 
Knudson “two-hit” hypothesis for neoplastic cancer progression [37, 38].  Further 
evidence for LOH as a mechanism for inherited CCM phenotypes comes from 
mouse models, which show that homozygous knock out of CCM1, 2, or 3 are 
embryonically lethal [3, 39-41].  Furthermore, studies with CCM1 and CCM2 
heterozygous mice in a p53 or Msh2 null background developed normally but 
displayed lesion formation with increasing age, phenocopying the human disease [8, 
42, 43].  Two studies, however, have demonstrated that there is a CCM protein 
haplo-insufficiency related increase in vascular leak in the brain and lung in CCM1 
and CCM2 heterozygous mice [3, 7].  This vascular leak was described post mortem 
through Evan’s blue dye extravasation and suggests that there is a defect in 
endothelial barrier, which may not be enough to result in lesion formation.  Further 
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histological analysis of human sections and tissue specific inactivation of CCM 
proteins in endothelial cells, neurons, and smooth muscle cells in mouse models 
have demonstrated that CCM phenotypes are isolated to endothelial cells [3, 37, 41].  
However, A recent study, utilizing a tissue specific conditional knock out of CCM3 
specifically in astrocytes from mice results in CCM lesion generation [44].  Therefore, 
it is widely accepted that the LOH mechanisms contribute to CCM lesion 
development; however, whether there are cells other than ECs affected by CCM 
protein loss remains controversial, and new models to describe these differences 
are needed. 
 
CCM lesion initiating cell(s) 
The cell of origin for the development of CCM lesions is unknown, and lesion 
formation most likely is a multifactorial process.  It is possible that CCMs arise from 
the loss of CCM-1, -2, or -3 in an endothelial cell which undergoes uncontrolled 
proliferation and sprouting angiogenesis or groups of endothelial cells accrue 
mutations concomitantly or slowly over time.  Increased proliferation remains 
controversial with several reports both in cell culture and in mouse models 
demonstrating an increased and decreased cell proliferative effect after loss of the 
CCM proteins [8, 40, 41, 45, 46].  These conflicting differences, at least in vivo, may 
be associated with the lesion stage and developmental timing [8, 46] (Table 1). A 
new mouse model, which investigated the developmental timing loss of CCM2, 
showed that lesions only formed during times of active angiogenesis in murine 
development and loss of CCM2 did not affect already formed quiescent blood 
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vessels [46].  This indicates there is a peripheral signaling cue that may promote 
lesion generation in cells lacking CCM proteins.  An attractive hypothesis, which has 
not been tested, is whether a circulating endothelial progenitor stem cell could lead 
to CCM lesion formation in adult tissues.  Along these lines, there have been 
numerous reports of circulating endothelial progenitor cells leading to adult 
angiogenesis and recruited bone marrow-derived circulating cells that can lead to 
adult neovascularization [47].  Thus, it would be possible that a circulating stem cell, 
which has accrued a mutation in one of the CCM proteins, could hone to a site of 
active adult angiogenesis and form a CCM lesion.  While speculative, this 
hypothesis could explain why CCM lesions form and from what cell they originate.  
The identification of the CCM cell(s) of origin will present an important discovery for 
the CCM field and may shed light into specific treatment paradigms for the 
prevention of lesions in familial CCM patients.  
 
CCM protein structure, function, and signaling 
CCM1 
The three genes CCM1, CCM2, and CCM3 are associated with global 
cytoskeletal mediated cell shape and polarity regulation by regulating RhoA and 
ROCK signaling (Fig 1.0 and 1.1). CCM1 was mapped as the first known gene to 
cause CCM through linkage analyses to 7q21.2 [48, 49].  CCM1 knock out is 
developmentally lethal from improper primary branchial arch artery formation [40].  
There have been over 100 independent germ line mutations that have been mapped 
to CCM1 and [14, 48-57].  The CCM1 gene product is a 51 KD protein that was first 
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discovered in a yeast-2-hybrid screen as an interactor with the small G-protein 
Rap1A [58].  This interaction was direct and occurred through its FERM (band 4.1 
Ezrin, Radixin, Moesin) domain, which was specific for Rap1A and not Ras [58]. The 
presence of four ankrin repeat domains within CCM1 are thought to establish 
additional protein-protein interactions. Interestingly, there are differently spliced 
isoforms of CCM1, which abrogate binding of CCM1 to Rap1A, and the expression 
of these different isoforms have been sequenced in familial CCM1 patients [59-61]. 
This CCM1/Rap1A interaction led researchers to investigate whether CCM1 
was a regulator of Rap1A signaling.  It was shown that CCM1 associates with the 
membrane proteins β-catenin, AF-6, and p120catenin, which was dependent upon 
the FERM domain dependent interaction of activated Rap1A and CCM1 [62].  
Functionally, the loss of this membrane protein association with CCM1 led to the 
delocalization of β-catenin, increased membrane permeability, and increased F-actin 
stress fiber formation. It was further shown that CCM1 moves through the cell 
through an association with microtubules, and it is subsequently displaced from the 
microtubule network at the membrane by GTP bound Rap1A [63]. An additional 
yeast two-hybrid screen demonstrated that CCM1 binds to the integrin binding 
protein ICAP-1 through an n-terminal NPXY motif within CCM1 [63]. Binding of 
ICAP-1 to CCM1 converts CCM1 from a closed to open form by displacing an 
intramolecular interaction between the CCM1 C-terminal FERM domain and an N-
terminal NPAY motif, promoting a ternary interaction between CCM1, ICAP-1, and 
Rap1A [63]. Overall, these experiments have delineated an important role for CCM1 
in regulating membrane junctions, integrin signaling, and F-actin formation [64]. 
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CCM1 was further established as a scaffolding protein after it was 
demonstrated that CCM1 directly binds to the CCM2/MEKK3 complex endogenously 
[65].  This binding is dependent upon the functional CCM2 PTB domain as a single 
point mutation abrogates the interaction [65].  Functionally, the CCM1/ICAP1/CCM2 
complex promotes cytoplasmic accumulation of CCM1 and ICAP1, which is further 
enhanced during hyperosmotic stress [65].  This phenotype has ascribed CCM2 as 
having a nuclear shuttling role for CCM1. The CCM1 scaffolding complex may also 
be functionally restricted to the endothelium.  Data supporting this idea was 
generated after the discovery of the mammalian ortholog to the zebrafish heart of 
glass receptor 1 (HEG1) [39].  HEG1 is required for the formation of a patent blood 
vascular network and is only expressed in endothelial cells [39].  The malformation 
following HEG1 knock out phenotypically copied CCM lesions with increased 
aberrant endothelial junctions [39, 66].  The CCM1/CCM2 complex co-
immunoprecipitates with HEG1 with CCM1 binding directly and CCM2 indirectly 
through its interaction with CCM1 [39].  These data suggest that CCM1 is further 
regulating the endothelial junctions through its association with HEG1, CCM2, and β-
catenin.  
CCM is a multifactorial disease process; therefore, it is not surprising that 
there have been reports of CCM1 function outside of the more investigated 
Rap1A/CCM2/HEG signaling (Table 1).  Recently, CCM1 has been described as 
promoting low reactive oxygen species (ROS) through FoxO1 mediated upregulation 
of the antioxidant protein SOD2 [67].  This functionally resulted in a transition from 
proliferative growth to quiescence [67].  The function of CCM proteins on cellular 
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growth has remained a point of contention with some groups reporting positive or 
negative growth promoting effects of CCM proteins (Table 1).  Recently, it was 
reported that CCM1 functions to activate NOTCH signaling through increased 
PIP2/3 induced AKT phosphorylation signaling to reduce aberrant angiogenesis and 
cell proliferation through inhibition of phospho-ERK1/2 [45].  Because CCM1 loss 
increased phospho-ERK1/2 the multi-kinase inhibitor Sorafenib, which is a potent 
ERK1/2 inhibitor, was used as a potential therapeutic to reduce aberrant endothelial 
sprouting [45].  In contrast to these results, our lab has consistently observed 
decreased proliferation after shRNA knock down of CCM1; these results may differ 
based upon the type of RNAi knock down technology employed.  Thus, a better 
approach may be to assess the in vitro proliferation potential of endothelial cells from 
CCM1 null mouse embryos    
Loss of CCM1 protein increases F-actin stress fiber formation, which is one of 
the hallmarks of an epithelial to mesenchymal transitions (EMT).  EMT is a normal 
developmental process, which becomes aberrantly occurs in metastatic cancer and 
fibrosis.  In general, an EMT involves a loss in cell polarity and increased migratory 
capability accompanied by a loss in epithelial cell markers.  These epithelial markers 
include adherens and tight junction proteins such as E-cadherin, ZO-1, Occludin, 
and Laminin. Mesenchymal cells gain expression of the EMT promoting transcription 
factors Snail, Slug, Twist, Goosecoid, Lef-1 and FOXC2 with a concomitant increase 
in the expression of mesenchymal markers α-SMA, N-cadherin, and Vimentin.  A 
major upstream driver behind EMT is through tumor derived growth factor beta 
(TGF-β) signaling.  TGF-β binds the TGF-βR1 and TGF-βR2 receptor tyrosine 
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kinases, which elicit a cellular response through phosphorylation of the Smad 
proteins.  Smads function as transcription factors promoting EMT gene expression. 
Endothelial to mesenchymal transition (EndMT) is a highly related process, and 
during embryogenesis endothelial cells undergo an EndMT to form the endocardial 
cells and heart valves [68].   
Interestingly, an inducible murine CCM1 knock out model generated lesions, 
which had highly disorganized VE-cadherin staining and an increase in the EMT 
markers N-cadherin, Slug, ID1, α-SMA CD44 and stem cell markers Sca1, CD44, 
and Klf4.  The expression of these markers were proportional to lesion size and 
were not present in the normal surrounding brain vascular tissue [69]. TGF-β 
signaling through BMP6 was found to be the upstream driver of this process 
selectively in brain endothelial cells. BMP6 is a strong mesenchymal inducer and in 
line with previous results, CCM1 loss reduced Notch signaling, which functioned to 
inhibit BMP6 expression [45, 69].  Importantly, small molecule inhibition of TGF-β 
signaling with either SB-431542 or LY-364947 reduced the number of lesions, 
prevented vascular leak, and restored correct astrocyte endothelial connections.  
This EndMT phenotype was further visualized in mouse CCM3 lesions and in human 
CCM lesions from CCM1 and CCM2 patients [69].  These data suggest that the 
CCM1 is playing an important role in promoting the Notch pathway, which 
antagonizes mesenchymal differentiation programs by blocking TGF-β signaling.  
With CCM2 and CCM3 also giving similar EndMT phenotypes it will be of importance 
to understand at a molecular level if CCM2 and CCM3 are also regulating Notch 
signaling and whether CCM1 coordinates this interaction.  Questions remain as to 
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whether the EndMT is a driver of lesion formation or if it is a developmental artifact 
detected during developmental angiogenesis in mice.  It will be interesting to 
determine if this EndMT is driven by RhoA/ROCK signals and whether it is reversible 
by ROCK inhibition. 
 
CCM2 
The second protein responsible for CCM (CCM2) was originally characterized 
as the Osmosensing Scaffold for MEKK3 (OSM). Sorbitol induced hyperosmotic 
shock causes dynamic actin polymerization and membrane ruffles that are regulated 
by Rac1 and MEKK3 mediated activation of p38. MEKK3 was used as a bait to 
identify potential unknown scaffolding proteins that may be important regulators of 
the cellular response to hyperosmotic shock [70].  The OSM/CCM2 gene product 
was identified in this screen and was shown to bind to MEKK3 and Rac1 at sites of 
active membrane ruffles following sorbitol treatment.  Furthermore, OSM/CCM2 co-
immunoprecipitated with actin in vitro and was required for activation of p38.  Knock 
down of CCM2 or MEKK3 alone led to decreased p38 activation and the double 
knock down synergistically decreased p38 activation, suggesting that CCM2 
coordinates MEKK3 subcellular localization. This study suggested that the Rac1-
OSM-MEKK3-p38 signaling cascade regulates cellular adaptation to osmotic stress 
similarly to the Hog1 stress signaling pathway in yeast [70].  Interestingly, MEKK3 
and p38 knock out animals die in utero from defective vascularization [71, 72].  It is 
unknown whether p38 signaling contributes to the development of CCM.  
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Concomitant with this work, OSM was genetically mapped as a novel PTB domain 
containing protein, which was the second gene responsible for CCM [73].   
The establishment of CCM2 as a scaffolding protein closely resembled the 
function of CCM1.  Hilder et al. 2007 utilized nanoelectrospray mass spectrometry 
and multidimensional protein identification technology (MudPIT) to map out all 
potential CCM2 interactors in mouse macrophage cells [74].  Importantly, in this 
unbiased proteomic approach the previously identified CCM interactors CCM1, 
MEKK3, Rac1, ICAP-1, and PDCD10 (CCM3) was identified as a novel CCM2 
interactor (Table 2 and Fig 1.3).  Follow up co-immunoprecipitation assays 
demonstrated that CCM3 binds CCM2 but not CCM1, and the three are found in a 
complex when overexpressed. Interestingly, a designed CCM2 F217A PTB domain 
mutant, which mimics CCM2 point mutations found in patients, abrogated the 
binding of many of the interacting proteins.  The PTB domain was not found to be 
essential for CCM3 binding as the crystal structure of CCM3 and CCM2 
demonstrated that binding was between the CCM3 FAT domain and CCM2 C-
terminal Karet domain [75].  This concept of the CCM1, -2, and -3 proteins working 
in complex helps to explain how the loss of three structurally different proteins yields 
indistinguishable clinical presentation and identical in vitro cell phenotypes.  Much 
work remains to describe how each of the CCM proteins function in this complex to 
regulate EC homeostasis.   
CCM2 knock out mice die mid gestation due to improper heart patterning and 
branchial arch artery formation, which phenocopies CCM1 knock out animal models 
[3, 40, 41].  These heart defects were endothelial cell autonomous as excision of the 
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CCM2 gene by cre recombinase in neurons and smooth muscle had no effect [3].  
This loss of CCM2 decreased endothelial tube morphogenesis, increased 
endothelial cell permeability, and increased F-actin stress fiber formation [3].  
However, in contrast to CCM1, the CCM2 knock out model did not affect β-catenin 
membrane localization, cellular proliferation, or phospho-Erk levels [3]. One of the 
major regulators of F-actin formation is the small GTPase RhoA.  Indeed, it was 
shown that CCM2 binds to RhoA and Rac1 but not CDC42 and loss of CCM2 only 
increases the basal activity of RhoA [3].  Importantly, direct inhibition of RhoA 
prenylation and membrane association by Simvistatin decreased actin stress fibers 
and membrane permeability.   Deregulated RhoA signaling concomitant with F-actin 
stress fibers and changes in cellular morphogenesis suggests that there is a major 
cytoskeletal defect component to the pathology of CCM.  
In CCM deficient endothelial cells, increased RhoA levels are due to the 
decreased degradation of RhoA as no changes in message levels have been 
detected [4, 5].  Crose et al. demonstrated that CCM2 binds to Smurf1 in a PTB and 
HECT domain dependent fashion, which functions to localize Smurf1 to the cell 
periphery where it ubiquitinates RhoA, leading to its proteasomal degradation [5].  
CCM2 was neither a substrate of Smurf1 nor did CCM2 affect the ability of Smurf1 to 
ubiquitinate other targets [5].  It was further shown that CCM2 functions to degrade 
RhoA in a dose dependent fashion, which was specific as the levels of other Smurf1 
substrates, such as MEKK2 were unchanged [5].  This role of CCM2 as a molecular 
shuttle for Smurf1 is analogous to the recruitment of Smurf1 to the membrane of 
epithelial cells by atypical PKCζ, which results in the ubiquitination and degradation 
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selectively of the active form of RhoA in the regulation of  protrusion formation [76].  
It is unknown whether CCM2 functions within the Par6-PKCς complex.  However, it 
was shown that loss of CCM2 endogenously stabilizes total RhoA protein [4].  Given 
that loss of CCM2 increases active RhoA, and Smurf1 increases active RhoA in 
other cell systems we hypothesized that the loss of Smurf1 would also increase 
active RhoA in endothelial cells through its interaction with CCM2.  Furthermore, it is 
unknown mechanistically how the loss of CCM1 and CCM3 increases RhoA levels, 
but it is likely that they work in conjunction with CCM2 to regulate Smurf1 dependent 
RhoA degradation.  Thus, degradation, in addition to GEF and GAP regulation of 
RhoA signaling, is likely a major pathway that underlies the etiology of CCM. 
Recently the CCM2 like or CCM2L paralog of CCM2 has been discovered, 
which developmentally antagonizes CCM2 function [77].  CCM2L is expressed 
solely in endothelial cells of the developing embryo at sites of active angiogenesis, 
and mice lacking CCM2L were severely retarded in their ability to form xenografted 
tumors due to lack of neovascularization [77].  Thus, CCM2L functions as a positive 
regulator of angiogenesis during development and tumor progression.  CCM2L 
competes with CCM2 for binding with CCM1 [77].  In contrast to CCM2, CCM2L 
cannot bind CCM3 and decouples the endothelial cell stabilizing effects of the CCM1, 
-2, and -3 complex [77].  Expression of CCM2L mimics the loss of CCM2 by 
increasing RhoA activation, and total RhoA protein, while also decreasing 
lumenogenesis in vitro [77].  These effects on RhoA protein levels could be through 
competition for Smurf1 binding and provides another example of where the 
disruption of the CCM complex may promote RhoA signaling.  Similar to the HEG 
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receptor, CCM2L mutations or overexpression have not been described in patients; 
however, with agreement in the field on the importance of sequencing CCM patient 
mutations, the identification additional genes involved in CCM pathology, such as 
HEG and CCM2L may be realized.  
In addition to its endothelial cell autonomous functions with CCM1 and CCM3, 
CCM2 regulates TrkA receptor tyrosine kinase dependent apoptosis [78, 79].  
Normally the TrkA receptor is involved in prosurvival signaling; however, in the case 
of pediatric neuroblastomas it functions as a pro-apoptotic protein [78].  Intriguingly, 
CCM2 was found to interact with the TrkA receptor with the requirement of both the 
PTB domain and Karet domain [78].  Loss of CCM2 in TrkA sensitive neuroblastoma 
cells increased cell survival, where as the overexpression of CCM2 decreased cell 
survival in a dose dependent fashion in TrkA insensitive cells [78].  Mechanistically, 
CCM2 functioned as a scaffolding protein, which bound to the germinal center 
kinase III (GCKIII) Stk25 and to the TrkA receptor [79].  CCM2 also bound to the 
GCKIII kinases Mst4 and Stk24, but this interaction had no effect on cell survival [79].  
The interaction between Stk25 and CCM2 is essential as knock down of Stk25 
protected neuroblastoma cells from TrkA- dependent cell death [79].  Furthermore, 
an intact kinase domain of Stk25 is also essential for TrkA- dependent cell death, as 
mutations in the active site abrogate its protective functions [79].  Interestingly, 
CCM2 has numerous phosphorylation sites and was shown to be phosphorylated by 
Stk25 [79].  The functional consequences of this phosphorylation is still unknown.  
Previously, CCM3 had been shown to directly bind to Mst4, Stk24, and Stk25 [6].  It 
will be of interest to determine if CCM2 also directly binds to these kinases and 
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whether the phosphorylation of CCM2 by Stk25 differentially affects CCM2 function.  
These studies will be of importance to further understanding the molecular 
mechanisms of how CCM2 contributes to CCM pathology.       
     
CCM3 
CCM3 appears to have more diverse functionality than that of CCM1 or 
CCM2. The gene product of CCM3 (PDCD10) was discovered as a protein that was 
up regulated in fibroblasts in response to pro-apoptotic stimuli and was later defined 
as the third gene responsible for CCM through mutational analysis [13, 80].  CCM3 
is a 25 Kd protein with a focal adhesion targeting (FAT) domain that is required for 
binding to CCM2 and paxillin [75].  Through proteomic analysis it has been shown to 
interact with the GCKIIIs Stk23, Stk25, Mst4, and the striatin-interacting 
phosphatase and kinase (STRIPAK) complex [81].  This association with the 
GCKIIIs Mst4, Stk24, and Stk25 has led to numerous potential functions of CCM3.  
CCM3 was found to associate in a complex with GCKIII kinases and the GM130 
Golgi protein at the cis side of the Golgi apparatus [82].  Functionally CCM3 led to 
the correct orientation of the Golgi during wound healing [82].  Golgi re-orientation is 
reflective of the cells ability to polarize correctly.  Interestingly, lack of polarization 
due impart to cytoskeletal defects in endothelial cells is one of the hallmarks of CCM 
[83].  It will be important to confirm these findings on CCM3 regulation of the Golgi in 
endothelial cells as CCM proteins are expressed in all cell types and may function 
differently from cell type to cell type.   
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Developmentally, the knock out of CCM3 by specific morpholinos in zebrafish 
results in branchial arch artery defects that are identical to that of CCM1 and CCM2 
[6].  Moreover, morpholino knock down of all Stk24 and Stk25 phenocopies the loss 
of CCM1, -2, or -3 in zebrafish, suggesting that there may be some functional 
redundancy between these two kinases; independent knock down had no 
developmental effect [6].  This single knock down effect is in contrast to the knock 
down of CCM3 alone, which has a profound defect on heart development [6].  In 
vitro, knock down of Stk25 increases endothelial monolayer permeability and F-actin 
stress fibers [6].  At a molecular level this interaction with GCKIII kinases promotes 
the STK24/25 mediated phosphorylation of moesin both in in vitro kinase assays and 
in vivo cell immunoflourescence [6].  Phospho-moesin negatively regulates RhoA, 
and promotes cell junction protein interactions and stability [6].  These data strongly 
link CCM3 both developmentally in vivo and in cell culture to the CCM specific 
phenotypes observed in CCM1 and CCM2 deficient cells.   
Similar to data generated in zebrafish, the murine CCM3 knock out mouse 
exhibited global primary vascularization defects with no surviving embryos past 
embryonic day 8.5 [31].  This defect was found to be due to decreased VEGFR2 
signaling as both phospho-VEGFR2 and total VEGFR2 levels were decreased as 
well as the VEGFR2 downstream targets phospho-PLC- γ  and phospho-AKT [84].  
Similar observations were seen in an independent study, which described CCM3 
positively regulates the Notch pathway and subsequent VEGFR2 signaling [85].  
CCM3 and downstream VEGFR2 loss decreased endothelial cell proliferation, 
increased apoptosis, led to disorganized junctional marker expression and 
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localization, and disrupted VEGF dependent in vitro tubulogenesis [31, 85].  
Mechanistically, CCM3 was found to bind to the VEGFR2 protein, which led to its 
stabilization by preventing receptor endocytosis [31].  This effect was specific to 
CCM3 as CCM2 overexpression was unable to increase VEGF [31].  These data 
point to a potential differing role for CCM3 in the generation of CCM3 lesions; 
however, it is unknown whether loss of CCM1 or CCM2 also decreases VEGFR2 
dependent signaling due to the disruption of the CCM1, -2, and -3 complex.  While, 
there are many examples of VEGFR2 activation increasing the activation state of 
RhoA and promoting aberrant angiogenesis in cancer, it is unknown what the effect 
of VEGFR2 loss upstream on the RhoA protein is in the CCM signaling environment 
[86].  
There remains some controversy about whether CCM3 functions in the same 
mechanistic pathway of CCM1 and CCM2 (Table 1). Chan et al. generated a 
separate CCM3 knock out mouse model, which growth arrests at embryonic day 
E8.0 before circulation is required and are embryonic lethal at day 13 [87].  This 
observation is in contrast to the CCM3 mouse model generated by He et al., which 
was lethal at day 8.5, failed to vascularize properly, and had noticeable cardiac 
structural defects [31].  In addition, CCM1 or CCM2 knock out mice die because of 
ineffective circulation and disrupted branchial arch artery development [3, 40].  The 
Chen et al. CCM3 knock out mouse developed both normal patent branchial arch 
arteries and cardiac structures but died due to venous rupture.  In vitro, loss of 
CCM3 was shown to not increase actin stress fibers or phospho Myosin Light Chain 
(pMLC), a common mechanism to CCM1 and CCM2. In contrast to He et al. CCM3 
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did not bind to VEGFR2, effect VEGFR2 levels, or effect VEGFR2 downstream 
signaling molecules [87]. These differing in vitro phenotypes could be explained by 
residual CCM3 present in cell culture.   
Further obfuscating the CCM3 mouse model phenotypic consensus, Louvi et 
al. described neural cell autonomous phenotypes in a third CCM3 knock out mouse 
model [44].  This study generated tissue conditional knock out mice under the 
control of the Nestin, GFAP, and Emx1 promoters [44].  All three neural specific 
knock out mice gave rose to enlarged brains and cerebrovascular defects [44].  
These observations are in contrast to the mouse models generated by Chen et al. 
and He et al, which had no observed neural phenotypes.  The developmental time 
points used to assess these neural effects could account for these conflicts.  The 
first two CCM3 mouse models described differences in vascular development during 
embryogenesis and assessed that there were no relevant phenotypes because mice 
were born.  These studies failed to examine whether brain tissue abnormalities 
existed where CCM lesions are the most symptomatic in patients.  The neural 
specific knock out mice generated by Louvi et al. were born but died at P3; tissue 
examination was restricted to the brain.  Thus, the knock out mice from the first two 
studies does not exclude the possibility of a neural cell autonomous function of 
CCM3. Importantly, the GFAP CCM3 knock out mouse described by Louvi et al. 
developed CCM lesions that pathologically are similar but not identical to human 
lesions.  One characteristic of these lesions was an increased proliferation of 
astrocytes and astrogliosis.  Global cytoskeletal deregulation was detected through 
RNA sequencing from laser microdissected lesions [44].  A gene signature for 
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proteins in the RhoA signaling pathway were more abundant than in controls [44].  
These data suggest that CCM3 may be functioning in neural tissues in a similar way 
to CCM1 and CCM2 in the endothelium by regulating RhoA signaling.  Moreover, the 
alternative CCM3 mouse models do no exclude CCM3 deficient neural tissues from 
promoting CCM lesion formation.  To establish the clinical relevancy of CCM3 loss in 
neurons it will be important to determine whether patient CCM3 lesions occur when 
CCM3 is absent in neural tissues and present in endothelial cells.  CCM lesions 
exhibit astrogliosis and those that exhibit the highest levels may result from 
mutations in CCM3 in neural tissues.  These experiments are now possible with 
CCM tissue banks and CCM3 antibodies that can be used for immunohistochemistry 
[87].    
 
Integrated CCM signaling 
All signaling work to date has described the three proteins as adapter-like 
proteins that lack enzymatic activity.  Clinically, mutations in the CCM proteins are 
indistinguishable and are only determined upon genetic sequencing analysis.  This 
finding has given rise to the notion that the CCM proteins function in a similar way. 
This hypothesis is supported by data from Hilder et al. where all three CCM proteins 
form a stable ternary complex in the cell [74].  It has also become clear that the CCM 
proteins have dynamic independent functions.  Therefore, it is likely that CCM1, 
CCM2, and CCM3 have both independent and dependent functions that regulate a 
common endothelial cell pathway.  Clinically, it would be advantageous to find 
therapeutic targets that could lead to the treatment of CCM 1, -2, and -3 mutations 
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as a single entity.  Currently, the only way to definitively distinguish between CCM1, 
-2, and -3 mutations is through expensive whole exome illumina DNA sequencing.  
Thus, there may be numerous independent molecular pathways that can lead to 
CCM lesion formation in mouse models and cell culture, but establishing the most 
accepted common pathway that is present in both CCM models and in patient 
lesions is paramount to establishing the first CCM therapy.  This concept would limit 
the time for drug development and FDA approval, which is both time and cost 
intensive.      
 
Small GTPase regulation 
With this goal in mind, the most phenotypically relevant hallmarks of CCM 
pathology are increased endothelial cell monolayer permeability with deregulated 
angiogenesis attributable to global changes in the actin cytoskeleton.  Work in the 
CCM field has conclusively shown that these hallmarks are due principally to 
deregulated RhoA signaling [83]. The role of deregulated RhoA signaling in CCM 
was first established from the experiments demonstrating that siRNA mediated loss 
of CCM1 led to an increase in F-actin stress fiber formation, a major in vitro 
phenotype occurring from overactive RhoA [62].  The Rho GTPases (RhoA, RhoB, 
and RhoC) are members of the Ras-related super family of small GTPases.  They 
function as molecular switches that regulate many cellular processes including cell 
cycle progression, migration, gene expression, and cytoskeletal dynamics.  This 
class of proteins cycles between an active GTP-bound state and an inactive GDP-
bound state.  Guanine nucleotide exchange factors (GEFs) activate GTPases by 
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exchanging GDP for GTP, and GTPase activating proteins (GAPs) inactivate them 
by promoting their intrinsic GTPase hydrolysis activity.  The third type of regulation is 
through guanine nucleotide dissociation inhibitors, which block spontaneous GDP to 
GTP exchange [86].     
 
Small GTPase regulation of endothelial junctions 
CCM phenotypes can be effectively narrowed down to the deregulation of 
important small GTPases in angiogenesis.  Part of the CCM protein complex 
function is to tightly regulate RhoA and Rap1 small GTPases.  Therefore it is 
important to understand how the RhoA, Rap1, CDC42, and Rac1 small GTPases 
control EC migration, angiogenic patterning, barrier function, and capillary stability.  
In response to an angiogenic cue such as VEGF, vessels sprout from preexisting 
vessels and migrate into new tissue through a RhoA, Rac1, and CDC42 mediated 
up regulation of matrix metallo proteins [88].  The tip cells, which lead this sprout, 
form lamellipodia and filopodia through activation of Rac1 and Cdc42, respectively 
[89].   Cdc42 and Rac1 then activate p21 activated kinase (PAK), which activates 
Lim kinase, which phosphorylates and inactivates the actin de-polymerization factor 
cofilin [90].  This process leads to F-actin polymerization and protrusion formation.  
When neighboring endothelial cell lamellipodia and filopodia contact each other they 
form adherens junction interactions that have been shown to be mediated by nectin 
proteins [91].  This junction formation results in a positive feed back loop leading to 
further leading edge activation of Cdc42 and Rac1, which interact with the WASP 
and WAVE, respectively [91].  This interaction leads to activation of the Arp2/3 actin 
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polymerizing proteins, leading to actin polymerization, branching, and fortification at 
sites of interendothelial junctions [91].  During initial migration, RhoA works 
coordinately with this system by activating several downstream effectors.  One is 
Rho associated kinase (ROCK1/2).  One branch of the RhoA Rock pathway results 
in a similar activation of Lim kinase and phosphorylation of cofilin.  This leads to F-
actin polymerization and stress fiber formation.  Concomitantly, active Rock also 
directly phosphorylates myosin light chain and myosin light chain phosphatase, 
which cumulatively promotes the association of actin and myosin II.   In addition to 
ROCK, RhoA activates mDia, which results in actin polymerization and stress fiber 
formation [92]. Overall, this cascade results in cell contraction along the cell 
cytoskeleton.  When cell contacts are made there is both inactivation and 
degradation of RhoA [91, 93].  With aberrant spatial and temporal activation of RhoA, 
the cell experiences aberrant contractile forces that physically separate junctional 
proteins [94].   These complex cytoskeletal dynamics in angiogenesis is tightly 
regulated in endothelial cells and recent studies suggest that CCM proteins may 
function to scaffold these regulators of the cytoskeletal GTPases.   
In addition to limiting opposing contractile forces through regulating RhoA 
degradation and activity, CCM proteins play a direct role in junctional stabilization.  
CCM1 binds to Rap1 through its FERM domain and recruits it to the membrane [62, 
95].  Once at the membrane, Rap1 functions to activate VAV2, a GEF for both 
CDC42 and Rac1, which promotes the stabilization of adherens junctions through 
VEcadherin [96].  In endothelial cells, RNAi knock down of CCM1 was able to 
prevent the Rap1 mediated stabilization of endothelial cell junctions [62].  
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Concomitantly, cell contraction and junctional instability is inhibited by the 
inactivation of RhoA through Rac1 mediated activation of p190RhoGAP [97].  
Interestingly, CCM1 co-immunoprecipitates with p120CTN, which also has 
redundant functions with Rac1 in activating p190RhoGAP [98].  This deregulation of 
the actin cytoskeleton and EC barrier through increased and overactive RhoA likely 
accounts for CCM pathology of leaky and aberrantly clustered capillaries.   
 
E3 ubiquitin ligase regulation of RhoA levels  
An emerging role in small GTPase regulation in addition to GEF, GAP, and 
GDI regulation, is through the ubiquitin proteasomal system (UPS) protein 
degradation pathway.  This pathway has been recognized as a major regulator of 
cellular function and has been shown to be an important mechanism for the 
regulation of the small GTPases Rac1, RhoA, and Rap1 and their respective GEFs 
and GAPs [99].  The signal for this pathway is carried out through addition of the 
ubiquitin modifier protein, a small peptide tag that binds covalently to acceptor lysine 
residues of specific substrates.  Following ubiquitination with a string of four or more 
ubiquitin proteins, the substrate is transported to the 26S proteasome where the 
substrate protein is degraded to peptide fragments and the ubiquitin protein tags are 
recycled.  This process occurs through three sequential ubiquitin activating enzymes 
(E1, E2, and E3).  A series of biochemical reactions occurs resulting in the 
recruitment of ubiquitin by E1 and the subsequent passing of ubiquitin from E1 to E2 
to E3 and then covalently to the substrate protein.  The number of ubiquitin ligases 
grows from one E1 ligase to several dozen E2 ligases to over 400 E3 ligases.  This 
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drastically increased number of E3 ubiquitin ligases yields an important dynamic 
range in substrate specificity [99].  The HECT domain family and RING/U-box family 
are the two families of E3 ligases shown to regulate the small GTPases.  RhoA 
levels are regulated by the SMAD ubiquitin regulatory factor (Smurf) family and the 
Cullin E3 ubiquitin ligases, HECT domain and RING/U-box family members, 
respectively [99].  
Smurf1 is a widely found E3 ubiquitin ligase, which has important roles in 
cellular growth, differentiation, and migration.  It has a C2 domain, WW1 and 2 
domains, and a catalytic HECT domain.  Smurf1 originally was discovered as an 
important regulator of TGF-β signaling during osteogenesis [100-102].  Specifically, 
it ubiquitinates the SMADs 1 and 5 (receptor SMADs), 4 (common SMAD), and 7 
(inhibitory SMAD) [103-105].  It also ubiquitinates type 1 and 2 BMP receptors and 
the TGF-β receptor 1[106, 107].  When phosphorylated at T306, Smurf1 is induced 
to ubiquitinate RhoA and has been shown to induce membrane protrusions, reduce 
actin stress fibers, and decrease cellular mobility in numerous cell systems [108].  
Smurf1 ubiquitination is inhibited by the protein synaptopodin and reduces stress 
fibers [109].  PKCζ localizes Smurf1 to the membrane where it interacts with Par6 
and degrades active RhoA at active sites of cellular protrusions.  CCM2 also 
relocates Smurf1 to the membrane at sites of active actin polymerization [5, 70]. It 
has been shown that CCM1 regulates the membrane localization of PKCζ and 
mPAR3 for correct establishment of cellular polarity [110]. 
Cellular polarity is carefully maintained through the coordinate regulation of 
the cytoskeleton through the small GTPases Rap1, RhoA, and CDC42.  CCM1 has 
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been shown to regulate the function and localization of the small GTPase Rap1A 
[95].  Similar to RhoA, Rap1A is degraded by the E3 ubiquitin ligase Smurf2. 
Functionally, this results in the establishment of correct neuronal polarity during 
development by the selective degradation of Rap1 in retracting neurites [111].  The 
Par polarity complex is responsible for localizing proteins for the establishment of 
proper cell polarity.  Just as the Smurf1 interaction with PKCζ, Smurf2 interacts with 
mPar3, which localizes Smurf2 properly [112].  Interestingly, Smurf2 has been 
shown to ubiquitinate and degrade Smurf1, and these two E3 ligases have opposing 
functions in development [113].  Thus, it is clear that the localization of the E3 
ubiquitin ligases and post translational modifications are paramount to their proper 
function.  Smurf1 and Smurf2 are highly similar; therefore, an outstanding question 
in the CCM field is whether Smurf2 regulates Rap1A levels in ECs and whether 
CCM proteins function to localize Smurf2.   
The Cullin ring ligase (CRL) family of ubiquitin ligases have broad functions 
and regulate the ubiquitination of many cell proteins [114].  There are six members 
of this family (Cul1, Cul2, Cul3, Cul4, Cul5, and Cul7); they function as scaffolds that 
link RING finger domain containing proteins, which bind to E2 ligases, and specific 
BTB domain containing substrate adapters that bind target proteins [115].  The cullin 
3 family member previously has been shown to ubiquitinate total RhoA protein 
leading to its degradation [116].  In cell culture, loss of either cullin 3 or the RhoA 
substrate adapter Bacurd increases RhoA protein, stress fibers, and inhibits cellular 
migration [116].  This process has been implicated in vascular smooth muscle 
function, which when deregulated increases blood pressure in a mouse hypertension 
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model [117].  Currently, there have been no investigations into cullin function in ECs 
and whether CCM proteins have any roles in modulating cullin regulation 
   
Rho-associated protein kinase (ROCK) 
The main effector of RhoA that results in broad cytoskeletal changes that 
underlies CCM specific phenotypes occurs through ROCK.  ROCK was initially 
identified as a RhoA effector that was involved in stress fiber and focal adhesion 
formation [118].  Currently, two highly similar isoforms of ROCK have been found 
(ROCK1 and ROCK2) [119].  Both ROCK1 and ROCK2 are required for normal 
development as knock out results in death soon after birth and in utero in ROCK1 
and ROCK2 knock out mice [119].  Both isoforms of ROCK are up regulated by the 
cytokines angiotensin II and interleukin-1B. Interestingly, an isoform difference in 
angiotensin converting enzyme (ACE) in patients with familial CCM has been found 
[84, 120].  Structurally, ROCKs contain a catalytic kinase domain, coiled coil domain 
that includes a Rho binding domain, and a pleckstrin-homology domain with a 
cysteine rich domain [121].  ROCK1 and ROCK2 are inactive until RhoA in its active 
GTP bound form binds to the Rho binding domain of either Rock1 or Rock2 
releasing their autoinhibited state [122].  ROCKs are ubiquitously expressed with 
ROCK II expression being the highest in the brain and in muscle tissue and ROCK I 
expression highest in the liver, spleen, lung, kidneys, and testis [118, 123].  ROCK 
proteins are found principally in the cytosol with a small fraction being membrane 
localized [118].  This membrane localization only occurs after activation of RhoA and 
subsequent RhoA and ROCK association [118].  After activation, ROCK 
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phosphorylates and regulates a myriad of substrates [121].  There is no empirical 
evidence that ROCK1 and ROCK2 phosphorylate alternate substrates, which is 
expected based upon their 92% kinase domain similarity [121].     
ROCK substrates include, myosin light chain phosphatase, myosin light chain, 
adducin, ezrin-radixin-moesin (ERM proteins), and LIM kinase [121]. These 
substrates are directly involved in regulating actin filament polymerization and actin 
cytoskeletal dynamics.  ROCKs provide a mechanism for smooth muscle contraction 
independently of calcium.  ROCK2 dependent phosphorylates myosin light chain on 
serine 19, which results in the association of actin and myosin [124].  In addition to 
phosphorylating MLC directly, ROCKs phosphorylate myosin light chain 
phosphatase, which increases the stoichiometry of phosphorylated myosin to non-
phosphorylated myosin [125].  This association results in the ATP dependent myosin 
cross bridge cycle of contraction. ROCK1 is involved in phosphorylating LIM kinase 
(LIMK) leading to subsequent actin stabilization through LIMK mediated 
phosphorylation and in activation of the actin severing protein cofilin [126-128].   
Aberrant RhoA signaling through its effector ROCK is a major driver behind 
CCM and numerous aspects of human disease, including multiple aspects of 
cardiovascular disease, tumor metastasis, vasospasm, edema, glaucoma, and CNS 
neurological disorders [129].  The important role of ROCKs in the pathogenesis of 
CCM lesions is just now being realized to be the underlying molecular basis to the 
pathology of CCM.  To this extent, positive pMLC2 staining has been reported in 
patient lesion samples that lack CCM1 or CCM2 expression but not in the normal 
flanking brain regions [7].  Furthermore, tight junction marker staining is decreased 
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in CCM patient lesion samples, consistent with the role of ROCKs in antagonizing 
junction stability [130, 131].  In vitro, positive pMLC2 immunoflourescent staining and 
immunoblotting has been shown in primary cell lines isolated from CCM1 and CCM2 
haplo-insufficient mice and in shRNA knock down endothelial cells for CCM1, CCM2, 
and CCM3 [7] [4].  These high levels of pMLC2 result in F-actin stress fiber 
formation indicating that ROCK activity is a physiological readout for CCM both in 
vivo and in vitro.  In addition, ROCK down regulates eNOS expression in endothelial 
cells through destabilization of eNOS mRNA, which leads to the activation of pro-
inflammatory pathways and reactive oxygen species (ROS) generation [132].  
Changes in redox state has been implicated in multiple facets of cardiovascular 
disease, including atherosclerosis, aortic aneurysm, and vascular stenosis [133].  In 
patient CCM lesions it has been shown that macrophages and lymphocytes enter 
into lesion sites and contribute to local inflammation around the lesion [134].  
ROCKs are known to activate the expression of pro-inflammatory cytokines, such as 
NF-ΚB that lead to the infiltration of inflammatory cells [135].  Thus, it will be 
important to determine if the inflammation found in CCM lesions is due directly to 
overactive ROCK or secondarily because of the decreased barrier protection, which 
allows for immune cell extravasation. 
In vitro assays that have been used to mimic in vivo phenotypes include 
permeability assays, tube formation assays, and migration assays.  Loss of the CCM 
proteins and the subsequent increase in ROCK activity results in decreased 
endothelial barrier that has been reproduced by both transwell permeability assay 
and trans endothelial resistance [8].  Interestingly, reduction in endothelial barrier 
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and stress fiber formation could also be obtained by overexpressing a mutant form 
of CCM2 (CCM2 F217A) that is unable to bind to CCM1, suggesting that CCM 
proteins must work in a complex to regulate RhoA and ROCK [7]. In addition to 
decreased barrier, high ROCK activity due to the loss of CCM proteins results in 
deregulated endothelial cell morphogenesis, cell shape programs, and migration [4, 
7].  With the loss of CCM proteins, endothelial cells are unable to properly form 
capillary like tube structures in both Matrigel and a 3D collagen matrix [4].  This 
phenotype has been replicated in two separate studies utilizing time-lapse 
microscopy and is thought to be due to an inability of the cell to form proper shape 
by sending out filopodial protrusions of the proper length or number [4, 7].  
Endothelial cell migration is also effected with the loss of CCM proteins, which is in 
line with the important role of RhoA and ROCK signaling in cell migration [4].  In a 
wound healing assay, CCM2 deficient cells are unable to migrate and reform a 
monolayer, and CCM1, CCM2, and CCM3 deficient ECs demonstrate a decreased 
invasive ability in Matrigel invasion assays [4, 5].  However, the distance of 
haptotactic migration towards fibronectin is increased in an active RhoA dependent 
manner as simvastatin was able to rescue this increased migration [3].  These 
differences could be assay and substrate dependent effects, and more experiments 
are needed to elucidate the effects of CCM protein loss on ROCK mediated 
endothelial cell migration that may play roles in the dysangiogenesis and vascular 
remodeling of early in vivo lesion formation.     
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Therapeutic avenues for CCM 
Simvastatin 
A promising avenue for the pharmacological treatment of CCM is through 
statins.  Statins are safe, effective, and have been used in treating 
hypercholesterolemia since 1987 [136].  Their efficacy comes from inhibiting 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA Reductase), which is an 
enzyme that controls the rate-limiting step in cholesterol biosynthesis [136].  Statins 
have been shown to decrease endothelial cell tone, reduce hypertension, and 
decrease arteriosclerosis [137].  Some of these “pleiotropic effects” come through 
the inhibition of RhoA localization through preventing its posttranslational prenylation. 
This inhibition has been shown in vitro to affect endothelial cell angiogenesis [138].  
Relevant to CCM, Whitehead et al. demonstrated that Simvistatin could rescue CCM 
phenotypes in vitro and in vivo.  The physiologically relevant EC50 Simvistatin to 
inhibit RhoA function, and whether this would be safe in patients needs to be 
determined.  Therefore, while feasibly challenging, it would be very interesting to 
initiate a retrospective clinical study on CCM patients that take statins and whether 
the overall outcome of these patients is improved.  
A phase 0 clinical trial was recently initiated for the use of statins in CCM 
titled, “Permeability MRI in Cerebral Cavernous Malformations Type 1 in New 
Mexico: Effects of Statins” (NCT01764451).  The study will follow CCM patients by 
MRI who were treated with placebo vs. Simvastatin.  Because statins are already 
FDA approved, the repurposing of this class of drugs for a new indication in the 
treatment of CCM will have minimal regulatory hurdles.  This is the first clinical trial 
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initiated for CCM, and it highlights the importance of how understanding the basic 
biology of CCM over the past decade has led to a potential therapeutic avenue.   
 
ROCK inhibitors in CCM 
Inhibition of ROCK is able to rescue in vitro and in vivo CCM phenotypes and 
constitutes a promising avenue for the pharmacological treatment of CCM.  Inhibition 
of RhoA and the activation of ROCKs by simvastatin rescues VEGF stimulated 
vascular leak in CCM2 deficient heterozygous mice [7].  This rescue was shown to 
be ROCK dependent as the ROCK selective inhibitor Y27632 was able to decrease 
stress fiber formation in CCM2 knock down cells [7].  Importantly, shRNA mediated 
ablation of ROCK2 was able to lower pMLC levels by immunoblotting in CCM1, 
CCM2, and CCM3 deficient endothelial cells [4].  Phenotypically, both knock down of 
ROCK2 and inhibition with Y27632 rescued Matrigel tube formation [4].  This effect 
is likely do to the rescue of cell shape by normalizing actin cystoskeleton dynamics 
as cells treated with Y27632 or ROCK2 stable knock down cells were able to extend 
multiple protrusions [4].  In addition to tube formation, ROCK inhibition by two 
structurally distinct inhibitors, H-1152 and Fasudil, reversed permeability and stress 
fiber defects in vitro in CCM1 and CCM2 knock down cells and decreased in vivo 
vascular leak stimulated by LPS in CCM1 and CCM2 heterozygous mice, 
respectively [7].   
Recently, two mouse models for CCM1 and CCM2 were generated that 
model the two hit hypothesis for loss of heterozygosity that lack either the mismatch 
repair gene 2 (Msh2) or p53 [8].  These mice randomly incur mutations that result in 
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the loss of the remaining CCM allele because of heightened genomic instability.  
These loss of function mutations result in CCM lesion generation, which 
pathologically mimics human CCM lesion development.  Importantly, when treated 
with a median dosage of Fasudil, these mice demonstrate a decrease in both lesion 
burden and severity as well as decreased hemosiderin deposition, a principle factor 
behind the seizures in CCM patients [8].  Due to phenotypes unrelated to CCM in 
the Msh2 deficient strain, namely lymphoma, mice were sacrificed at 5 months of 
age; therefore, no long term morbidity studies following Fasudil treatment can be 
done with these mice [8].  Regardless, the in vitro and in vivo completed at this point 
points to ROCK inhibition as a promising therapeutic option for CCM. 
ROCK inhibition represents and important avenue for the treatment of CCM.  
In Japan, the ATP competitive inhibitor, Fasudil has been successfully used for the 
treatment of cerebral vasospasm after subarachnoid hemorrhage since 1995, and 
displays positive outcomes with little to no adverse side effects [139].  Therefore, 
Fasudil has been used successfully in small-scale clinical trials for the treatment of 
multiple cardiovascular diseases, including hypertension, coronary artery disease, 
coronary vasospasm, ischemia, and infarction [140]. The principal effect of Fasudil 
has been to inhibit ROCK, resulting in decreased smooth muscle contraction, 
increased eNOS expression, and reduced inflammation [140].  However, first 
generation ROCK inhibitors such as Fasudil, Y-27632, and H1152 have been shown 
to have off target effects and inhibit other kinases as well [140].  Thus, the success 
in these trials has led to the development of isoform specific and more selective 
ROCK inhibitors by pharmaceutical companies.  
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Rationale for an iPS cell disease model for CCM 
The work from current models has allowed for the understanding of many 
complex phenotypes; however, it is unknown how these findings will translate to 
patients.  Thus, most cell culture models of CCM entail the use of finite endothelial 
cells, which have limited usefulness in fully understanding the development of CCM 
lesions. Mouse models are now beginning to be utilized; however, generating an 
accurate animal model of spontaneous CCM, which encompasses the genetic 
diversity of human patients, is not possible. This basic disconnect underlines the 
importance of generating new patient specific models of CCM. Thus, understanding 
CCM in the context of patient cells will verify current disease mechanisms, allow for 
the discovery of new deregulated pathways in CCM, and test therapeutics for 
efficacy and toxicity (Fig 1.2).   
Recent advances in cell biology have made the study of patient cells from 
rare or hard to study diseases possible.  This importance of studying diseased cells 
from patients has been fully recognized for many years.  However, the isolation and 
propagation procedures are often complicated by access, purity after isolation and 
slow cellular growth rates.  Seminal work from the laboratory of Shinya Yamanaka 
demonstrated that fully differentiated fibroblasts can be induced to a pluripotent state 
or become induced pluripotent stem cells (iPS) through the ectopic introduction of 
transcription factors, which officially initiated the “reprogramming” era in cell biology 
[141, 142].     
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This establishment of reprogramming was built upon the initial work of James 
Thomson, who elucidated the growth conditions for pluripotent human embryonic 
stem cells (hESCs), and the reprogramming work in the field of somatic cell nuclear 
transfer (SCNT) [143, 144].  The molecular mechanisms driving the pluripotency 
machinery was mapped out, which led to the initial screen that identified Oct4, Sox2, 
KLF4, and cMyc as reprogramming factors known as the classical “Yamanaka 
cocktail” [142, 145].  Since the initial reprogramming experiments, new techniques, 
which avoid viral integration have been established, and there has been significant 
progress in elucidating the molecular mechanisms governing reprogramming [146]. 
These new methods reduce the chance that transgenes will be reactivated and 
inherently generate more homogenous iPS cell lines albeit at a cost of 
reprogramming efficiency. 
The importance of hESCs cannot be understated, as they are the gold 
standard for determining how to differentiate pluripotent stem cells to relevant 
terminally differentiated daughter cell types.  hESCs are normally occurring 
developmental cells, which are isolated from a pre-implantation embryo [144].  
These cells are in contrast to iPS cells, which are forcibly derived from somatic cells 
through forced gene overexpression or chemical means [146].  On a superficial level 
these cells morphologically look the same and express the core pluripotency 
regulators at similar levels.  However, the ability of these cells to differentiate into 
different daughter cell types is highly variable and is dependent upon the starting cell 
of origin.  In fact, it has been shown that depending on the starting somatic cell being 
reprogrammed there is an “epigenetic memory” effect, where by the reprogrammed 
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cell has left over epigenetic markers, which pushes the iPS cell preferentially back 
into the original somatic cell type [147, 148].  For example, iPS cells generated from 
pancreatic islet beta-cells retained open chromatin marks for beta-cell related genes 
and retained a higher efficiency to differentiate to beta-cells [149].  This epigenetic 
memory effect typically becomes less pronounced with time in culture or with 
treatment with epigenetic modifying drugs such as, trichostatin A and 5-azacytidine 
[150].  In situations where directed differentiation is challenging this epigenetic 
memory can be exploited by selecting the same cell of origin that the iPS cells will 
be in re-differentiated back into for study or therapy. Therefore, the somatic cell type 
of choice for initiating reprogramming becomes important when considering 
differentiation potential and kinetics.  
The proper differentiation of pluripotent stem cells to a desired daughter cell 
type has been a major hurdle for researchers.  Knowledge obtained from in vivo 
mammalian and chick development has been in valuable in establishing the 
conditions for differentiating pluripotent stem cells, which involves recapitulating 
many signaling aspects of normal development (Fig 1.3).  Accordingly, different 
cytokines or small molecules that are agonists or antagonists for major signaling 
pathways are utilized to commit pluripotent stem cells to the ectoderm, mesoderm, 
or endoderm germ layers with further cytokines or small molecules added to specify 
more specific lineage commitments.  The results of these experiments typically 
produce immature somatic cells, which are heterogeneous in respect to cellular 
subtype.  The limitation to obtaining an exact cell type needed for study is limited by 
the knowledge of developmental pathways and signaling molecules that normally 
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result in the in vivo development of that cell.  Purifying the target cell is typically 
accomplished by cell surface marker analysis either by flow cytometry or micro bead 
purification strategies.  To date, neurons, myocardiocytes, haematopoietic cells, 
endothelial cells, hepatocytes, pancreatic cells, smooth muscle cells, and numerous 
other cell types have been generated from first hESCs followed by hiPS cells.  
Importantly, the field has begun to establish protocols for generating specific 
subtypes of each type of these cells.  For example, specific dopaminergic neurons 
found only in the striatum have been developed for the in vitro study of Parkinson’s 
disease and cortical neurons.  Many cell types require more substantial functional 
development, meaning these cell types such as cardiomyocytes must contract in a 
directed manor to fully develop into a differentiated cell type, which are now being 
defined [151]. 
The generation of patient specific cell therapy has been a major focus for 
stem cell researchers. Thus, the establishment of hESCs and hiPS cells that can 
differentiate into a myriad of cell types was thought to be a major break through in 
the regenerative medicine field.  These cells represented a unique and transient 
developmental cell type with the ability to differentiate along the three germ layers, 
mimicking in vivo gastrulation to any and all cells that constitute the human body. 
Furthermore, they expressed telomerase and were immortal until properly 
differentiated [152].  Therefore, it was initially thought that these cells would 
generate a plethora of regenerative cells for the treatment of diseases ranging from 
neurodegenerative disorders, heart disease, and spinal cord injury.  
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Along these lines, two breakthrough studies by the Jaenisch group at MIT 
demonstrated the powerful regenerative potential of iPS cells in the mouse.  Hanna 
et al. set out to demonstrate that iPS cells could ameliorate sickle cell anemia [153].  
To accomplish this goal, they generated disease miPS cells from a humanized sickle 
cell anemia mouse, which had the murine α and β globin genes replaced with the 
human sickle cell globin genes. With homologous recombindation, they were able to 
correct the gene mutations and re-transplant in vitro differentiated bone marrow 
precursor cells back into an irradiated mouse.   These genetically corrected miPS 
cell derived precursor cells were able to reconstitute a healthy bone marrow and 
drastically increase erythrocyte function.  The second study by Wernig et al. used 
iPS cells to correct Parkinson’s disease phenotypes following administration of 6-
hydroxy dopamine [154].  They established that iPS cells differentiated in vitro to 
dopamine neurons were able to functionally integrate into the mid brain, express 
tyrosine hydroxylase, and reverse the behavioral phenotypes associated with 
Parkinson’s disease. 
Despite these promising results, the regenerative medicine applications of 
hESCs and hiPS cells have yet to be realized with the only study receiving FDA 
approval for clinical trials in the treatment of retinal degeneration being recently 
abandoned by Geron Corporation [155]. hESCs have been limited from the 
beginning by host vs. graft rejection issues and careful HLA evaluation of the hESC 
line is required, and immunosuppressive agents may be needed [156-158].  
Principally, concerns remain with the possibility of hIPS cells forming aberrant 
tumors.  This possibility of tumor formation is especially of concern in iPS cells 
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generated with integrating retro or lenti viruses that encode oncogenes, such as 
cMyc, which have the possibility of aberrant transgene re-activation [159].  
Furthermore, if residual pluripotent stem cells remain in the transplanted culture 
there is a possibility for teratoma formation. Most of the preclinical iPS cell therapy 
studies have been done in immune suppressed mice, and the level of aberrant 
teratoma formation is directly correlated to the level of immunosuppression [160]. 
Interestingly, a recent study demonstrated that mice were immunogenic to 
syngeneic iPS cell teratomas and not to ES cells teratomas due to aberrant gene 
expression [161].  Therefore more work needs to be done to establish whether iPS 
cells truly will not elicit an immune response, differentiate and integrate into the host 
properly, and not be tumorgenic. 
The use of iPS cells in the immediate term has been repurposed from cell 
therapy to in vitro diagnostics.  In this context, iPS cells represent a unique patient-
specific disease modeling and drug screening platform technology [162].  The best 
diseases to model with iPS cells are monogenetic with cell autonomous disease 
presentation [163].  iPS cells are grown and differentiated in an in vitro environment 
that is much different than the in vivo environment of the patient; therefore, the 
phenotypes need to be inherent to the cell rather than environmentally induced.  
One of the most impressive examples of iPS based disease modeling comes from 
the modeling of familial dysautonomia (FD) [164].  This disease is caused by a 
single mutation in the IKBKAP gene, which leads to gene silencing and peripheral 
neuropathy.  Using lineage differentiation, it was found that the loss of this gene 
solely occurred in neural crest progenitor cells.  Furthermore, upon screening small 
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molecules, the plant protein kinetin was found to rescue the in vitro phenotypes.  
This avenue of patient specific in vitro research has become highly fruitful with 
patient iPS cells being generated from over 24 different diseases [163].  Importantly 
CCM has these similar characteristics in that it is cell autonomous and monogenetic 
with distinct phenotypic assays. 
Another facet of disease modeling with iPS cells or hESCs cells comes 
following the advent of next generation genome editing technologies.  Gene 
targeting of mouse embryonic stem cells (mESCs) through homologous 
recombination has been realized as one of the great breakthroughs in biomedical 
science allowing for the generation of animal models of human genetic disease [165].  
This technique has been hard to employ with hESCs with low rates of recombination. 
To address this issue, researchers have generated zinc finger mediated Fok1 fusion 
protein nucleases, Talens and Crispr [166].  Each of these methods increase the 
efficiency of gene recombination by using a rationally designed DNA binding domain, 
fused to an endonuclease domain [167].  The specificity of zinc fingers and Talens is 
established by two anti-parallel engineered DNA binding domains bound to the Fok1 
endonuclease, which cuts each respective strand that generates a double strand 
break (DSB) [77].  Crispr technology uses guide RNA and the Cas9 endonuclease 
ribonucleoprotein complex to align and generate a DSB.  The template DNA is then 
recombined into the host genome through non-homologous end joining (NHEJ).  
When modeling patient diseases, these technologies are invaluable because they 
will allow the generation of diseased control iPS cell lines by knocking out the gene 
that is implicated in the onset of the disease.  These cells will be invaluable for 
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establishing if patient cell phenotypes are monogenic or polygenic.  Furthermore, 
these cells will help establish important phenotypes from those that occur simply 
from iPS line to iPS line clonal variance.  
CCM is an autosomal dominant disease with incomplete penetrance, which 
requires LOH.  The phenotypic severity and number of lesions during life varies 
widely among patients Therefore, CCM is a disease that would benefit greatly from 
an iPS disease model. With this model it will be possible to obtain cells from patients 
and reprogram these cells to iPS cells.  With established differentiation paradigms 
and the ability to take advantage of cellular epigenetic memory mechanisms in iPS 
cells, we will be able to establish the cell autonomous disease phenotypes from 
CCM mutant cells.  Furthermore, we will be able to use genome-editing technologies 
to simulate disease progression by removing the healthy allele from CCM patients.  
One of the most exciting avenues will be to utilize genome editing to knock in 
fluorescent tags to CCM proteins to visualize their endogenous functions across a 
myriad of cell types including endothelial cells.  These modified cells will allow for an 
unprecedented ability to determine the endothelial cell functions of CCM proteins 
from the functions of CCM proteins in other cells.  More clinically relevant, these iPS 
cells will allow for the validation of CCM phenotypes from patients and also present 
the possibility of patient-specific small molecule drug screening, while also 
addressing some of the controversies in the CCM field.   
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Objectives 
In recent years there has been much progress into establishing the 
mechanisms behind CCM pathophysiology.  This process started with the molecular 
cloning of the three CCM genes and has progressed to the point of initiating the first 
clinical trail in CCM.  In lieu of these milestones, much work is needed to fully 
understand the complex CCM protein-signaling network in cells from actual CCM 
patients.  There is little known about the involvement of kinases as drivers of CCM 
phenotypes either up or downstream of RhoA.  Kinases are important signaling 
molecules that translate extracellular cues to cell changes, of which many are 
targetable and have FDA approved inhibitors currently available.  Therefore, an 
objective of this project is to profile the kinome in an unbiased way to 
discover important regulators of the endothelium that are deregulated in CCM 
protein deficient ECs.  This objective was accomplished through multiplexed 
kinase inhibitor beads coupled with quantitative mass spectrometry.  We found many 
conserved kinases that were deregulated in both CCM protein deficient ECs from 
mouse and human.  We validated previously identified kinases described in CCM 
biology and expanded this list with many more kinases that directly regulate the actin 
cytoskeleton and the previously described RhoA signaling node.  Further validation 
of these data will provide additional kinase-mediated drivers of CCM phenotypes.    
Our laboratory has previously established that the loss of any one of the CCM 
proteins increases both the active and total pools of RhoA without any increase in 
message level.  Overall, these elevated levels of RhoA increase F-actin stress fibers 
and EC permeability (Fig 1.0).  Thus, we posit that that the central function of the 
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CCM proteins in ECs is to regulate RhoA and the actin cytoskeleton.  However, an 
outstanding question in the CCM field is how RhoA levels are increased 
following CCM protein loss.  Thus, we seek to further define how RhoA is 
regulated in ECs.  Specifically, we focused on how the degradation of RhoA is a 
molecular mechanism contributing to an increase in RhoA signaling.  To this extent 
we show that the ubiquitinated status of GTP bound RhoA is decreased in CCM or 
Smurf1 protein deficient ECs.  We further hypothesize that the CCM protein ternary 
complex coordinates Smurf1 function or localization and facilitates the Smurf1 
mediated degradation of GTP bound RhoA.    
CCM is a multifactorial disease, which varies greatly in the severity of lesions 
from patient to patient.  Despite this known facet of CCM, there has been little study 
of the phenotypes in cells from CCM patients.  Most all of the studies from CCM 
patients have been from surgically resected lesions, which can only provide 
retrospective information about CCM lesion genesis.  Thus, the further 
understanding of the molecular pathways driving defects in ECs and how individual 
patient genetic backgrounds influence this process is greatly needed.  Furthermore, 
it is unknown whether heterozygous CCM patients have defects in EC function.  
Therefore, the final objective of this thesis is to establish a feasible model for 
studying diseased patient endothelial cells.  We undertook this objective by 
establishing endothelial progenitor derived ECs (EPC-ECs) and hESCs as valid 
models for the study of CCM phenotypes.  We further were able to generate iPS 
cells from these EPC-ECs as a novel cell source for iPS cell generation.  The 
relevance of this approach is two-fold; EPC-ECs allow for immediate study of CCM 
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phenotypes from patients, and iPS cells allow for the generation of an immortalized 
CCM patient cell bank.  The proof of concept studies provided here will allow for the 
generation of iPS cells for the study of patient ECs and potentially uncover novel 
mechanisms driving CCM phenotypes, which can only be realized in CCM patient 
cells.  
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Figure 1.0.  Core CCM signaling circuitry in endothelial cells.  Activated GTP 
bound RhoA is at the core of driving CCM phenotypes.  RhoA GTP activates ROCK 
and mDia, leading to actin polymerization, stabilization, and cross linking with 
myosin.  In normal cells CCM1, -2, and -3 are in complex with each other and 
regulate the levels of active RhoA.  In this complex, CCM1 binds HEG1 and CDH5 
(vecadherin), which stabilizes vecadherin juntions while also regulating Rap1 
function.  CCM3 binds to the GCKIII steril kinases (STK), which phosphorylate ezrin 
radixin moeisin proteins that antagonize GTP bound RhoA.  CCM2 interacts with 
Smurf1 at sites of actin polymerization at the cell membrane to ubiquitinate and 
degrade active GTP bound RhoA. Smurf2 and Cullin3 ubiquitinate and degrade 
Rap1 and GDP bound RhoA, respectively.   
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Figure 1.1.  Defined structural domains and interacting proteins for CCM1, -2, 
and -3.   Interactions were defined using multiple techniques, including co-
immunoprecipitation coupled with mass spectroscopy and/or immunoblotting and 
yeast 2-hybrid screens. The CCM1 FERM (Four-point-one, Ezrin, Radixin, Moesin) 
domain binds multiple proteins. The NPAY, NPLF and NPYF sequences in CCM1 
bind to phosphotyrosine-binding (PTB) domains. CCM1 also encodes a nuclear 
localization (NLS) sequence. CCM2 encodes a PTB domain and Karet domain.  
CCM3 has a FRAP-ATM-TRAP (FAT) domain that binds MST4, STK24 and STK25 
serine/threonine protein kinases.  
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Figure 1.2.  Strategy for developing and utilizing a CCM patient specifc iPS 
disease library.  iPS technology allows for the development of a normal 
immortalized library of CCM patient cells.  Blood cells can be obtained from CCM 
patients and transiently amplified.  Either traditional retroviral (integrating) or newer 
sendai viral (non-integrating) approaches can be used to infect these primary patient 
cells.  After two weeks to one month, immortalized normal iPS colonies appear for 
expansion.  These cells can then be differentiated to all cell types of the body.  
Disease specific phenotypes can be studied and new pharmacologic therapies can 
be validated in the context of the CCM patient genetic background.  Next generation 
genomic targeting approaches will allow for the knock-in of fluorescent tags to study 
endogenous CCM protein function in real time. 
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Figure 1.3.  Differentiation strategy of pluripotent stem cells to endothelium.  
Pluripotent cells must be differentiated through a posterior-like primitive streak 
intermediate.  This process is initiated through TGF-β and Wnt cytokine addition.  
Hemangioblast-like cells are obtained by the addition of Activin A.  These cells are 
then driven to the vasculature by addition of VEGF.  Endothelial characteristics are 
maintained by TGF-β inhibition. 
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Table 1.  Phenotypes associated with CCM1, -2, and -3 protein loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. 
Phenotype CCM1 CCM2 CCM3 
Activates p38  Uhlik et al. (2003)  
Anti-oxidant function  Goitre et al. (2010)  Fidalgo et al. (2012) 
Branchial arch artery 
defects Whitehead et al. (2004) Boulday et al. (2009)  
Endothelial cell 
autonomous 
Whitehead et al. (2004); 
Guzeloglu-Kayisli et al. 
(2004); Plummer et al. 
(2004); McDonald et al. 
(2010) 
Boulday et al. (2009); 
Boulday et al. (2011); 
Cunningham et al. 
(2011); McDonald et al. 
(2010) Chan et al. (2010) 
Increases EndMT 
markers Maddaluno et al. (2013) Maddaluno et al. (2013) Maddaluno et al. (2013) 
Increases Phospho 
Moesin    Zhen et al. (2010) 
Loss elevates active 
RhoA 
Borikova et al. (2010); 
Stockton et al. (2010) 
Whitehead et al. 
(2009);Borikova et al. 
(2010); Stockton et al. 
(2010); Zheng et al. ( 
2012) 
Borikova et al. (2010); 
Zheng et al. (2010) 
Loss elevates F-actin 
stress fibers 
Glading et al. (2007); 
Stockton et al. (2010) 
Crose et al. (2009); 
Whitehead et al. (2009); 
Zheng et al. (2010) Zheng et al. (2010) 
Loss elevates phospho 
MLC2 
Borikova et al. (2010); 
Stockton et al. (2010) 
Borikova et al. (2010); 
Stockton et al. (2010) Borikova et al. (2010) 
Loss elevates total RhoA Borikova et al. (2010) 
Crose et al. 
(2009);Borikova et al. 
(2010); Zheng et al .( 
2012) Borikova et al. (2010) 
Membrane Localized 
Zawistowski et al. (2005); 
Glading et al. (2007); 
Uhlik et al. (2003); 
Zawistowski et al. (2005); 
Crose et al. (2009)  Zheng et al. (2010) 
Neural cell autonomous      Louvi et al. (2011) 
Nuclear Localized Zawistowski et al. (2005) Zawistowski et al. (2005)   
Prevents Cell 
proliferation 
Whitehead et al. (2004); 
Wustehube et al. (2010); 
McDonald et al. (2010) 
McDonald et al. (2010), 
Boulday et al. (2011) Zhu et al. (2010) 
Prevents endothelial cell  
sprouting Wustehube et al. (2010)   
Prevents endothelial cell 
migration Wustehube et al. (2010)   
Promotes Cell 
proliferation    Ma et al. (2007) 
Promotes endothelial cell 
migration Borikova et al. (2010) 
 Crose et al. (2009); 
Borikova et al. (2010) Borikova et al. (2010) 
Promotes endothelial cell 
sprouting Borikova et al. (2010) Borikova et al. (2010) Borikova et al. (2010) 
Promotes 
Lumenogenesis 
Borikova et al. (2010); 
Lampugnani et al. (2010) 
Kleaveland et al. (2009); 
Whiteheat et al. (2009); 
Borikova et al. (2010) Borikova et al. (2010) 
Regulates Apoptosis  Harel et al. (2009) Chen et al. (2009) 
Regulates the Notch 
Pathway 
Whitehead et al. 
(2004);Wustenhube et al. 
(2010); Maddaluno et al. 
(2013)   
He et al. (2010); You et 
al. (2013) 
Regulates Tumor 
Formation   Haerl et al. (2009)  
Stabilizes VEGFR2 
signalling    He et al. (2010);  
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Table 2.  Proteins that have been shown in the literature to interact with CCM1, 
-2, and -3. 
 
 
 
 
Interactor CCM1 CCM2 CCM3 
Binds ICAP 
Zawistowski et al. (2002); 
Liu and Boggon (2013); 
Liu et al. (2013)    
Binds with GCKIIIs  Costa et al. (2012). 
Ma et al. (2007); Fidalgo et 
al. (2010); Zheng et al. 
(2010); Ceccarelli et al. 
(2011); 
Binds PP2A Goudreault et al. 2007    
Binds Microtubules Gunel et al. (2002)   
Binds Actin  
Uhlik et al. (2003); 
Hilder et al. (2007)   
Binds HEG1 
receptor Kleaveland et al. (2009)    
Binds to Rap1 
Serebriiskii et al. (1997); 
Liu et al. (2012); Li et al. 
(2012)    
Binds RhoA  
Whitehead et al. 
(2009)   
Binds Rac1  
Uhlik et al. (2003); 
Whitehead et al. 
(2009)   
Binds MEKK3  
Uhlik et al. (2003); 
Hilder et al. (2007)   
Binds CCM1  
Zawistowski et al. 
(2005); Hilder et al. 
(2007);    
Binds CCM2 Hilder et al. (2007)  
Hilder et al. (2007); Li et al. 
(2010) 
Binds to Paxillin   Li et al. (2011) 
Binds CCM3  Hilder et al. (2003)  
Binds Smurf1  Crose et al. (2009)  
Binds to the Golgi 
apparatus    Fidalgo et al. (2010) 
Binds to 
Vecadherin/b-
catenin   Glading et al. (2007)  
 
 
 
 
 
II. Materials and Methods 
 
Chapter III  
Cell culture 
 Huvecs (Lonza) were maintained in EGM-2 media (Lonza) and passaged every 
3 to 4 days for up to 5 passages at a 1:5 sub-culturing ratio with media renewal 
every other day.  MEECs (gift from Dr. Leslie Parise) and BEND.3 (ATCC) were 
maintained in DMEM (Gibco) supplemented with 3% fetal bovine serum (FBS; 
Atlantis Biologicals) and 1% penicillin/streptomycin (Gibco) at a 1:10 sub-culturing 
ratio with media renewal every other day.  HEK 293T (ATCC) cells were maintained 
in DMEM (Gibco) supplemented with 10% FBS (Atlantis Biologicals) passaged every 
3 days at a 1:10 sub-culturing ratio with media renewal every 3 days.      
 
Establishment of CCM1, -2, and -3 knockdown cell lines 
 PLKO.1 specific lentiviral gene shRNAs for human CCM1, -2, and -3 were 
acquired from the UNCCH Lentiviral Core Facility. Lentivirus was generated by the 
transient transfection of 293T packaging cells with Lipofectamine 2000 and Plus 
Reagent (Invitrogen).  Virus was subsequently purified by ultracentrifugation and 
suspended in PBS.  Subconfluent cultures of cells were infected at a ratio of 1:4 viral 
producing cells seeded to host cells (i.e. 1/4th volume of virus generated from a 293T 
producing plate was incubated on the same size host cell plate). Viral particles were 
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incubated on cells for 48 hours in 8 µg/mL polybrene; cells were then placed in 
2.5 µg/mL puromycin to select for transduced cells.  Five shRNAs for each gene 
were initially validated for knock down efficiency.  Two shRNAs for each gene were 
found to have similar phenotypes and knock down efficiency, and were used to 
control for off target shRNA effects.  Knockdown efficiency was quantitative real time 
PCR (qRT-PCR) with primers specific for each CCM gene. Phenotypic experiments 
were conducted between 7 and 14 days after infection to ensure stable protein 
knockdown. 
 
Immunofluorescence  
 Glass coverslips were placed in 24 well plates coated with Matrigel (BD 
Biosciences) diluted 1:50 in DMEM for 1 hr at 37°C.  8.5x104 bEND.3 or Huvec cells 
were plated in each cover slipped well of a 24-well cell culture dish and incubated 
overnight. Seeded cells were fixed in a 3%  paraformaldehyde/sucrose/PBS solution, 
permeabilized with .1% Triton X-100/PBS, and the Actin cytoskeleton was stained 
with Alexafluor 488-Phalloidin (or 595-Phalloidin). Phospho-cofilin imaging was 
obtained after cells were fixed in 4% paraformaldehyde/PBS solution, and 
permeabilized with .1% Triton X-100/PBS. Anti-phospho-cofilin (Cell Signalling) and 
anti-rabbit Alexafluor 595 secondary antibodies (Invitrogen) were incubated at room 
temperature for 2 hours  and 1 hour in the dark, respectively. Hoechst dye (Sigma) 
was used to visualize nuclei. Images were taken in oil at a magnification of 40x 
(Zeiss Axiovert 200) with atleast 5 fields of view.  Stress fibers and phospho-cofilin 
levels were quantitated using a Nikon 80i Research Upright Microscope (Nikon, 
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Tokyo, Japan) equipped with Surveyor Software with TurboScan (Objective Imaging, 
Kansasville, WI). Image montages were acquired with a Qimaging Retiga-EXi 
camera (Qimaging, Surrey, BC, Canada). Cell area was determined by cropping 
images and manually masking each cell with ImageJ software (NIH).  Geometric 
features of the cells were automatically extracted with Cellprofiler software (Broad 
Institute of Harvard and MIT, Cambridge, MA). 
 
Immunohistochemistry 
 Dr. Nana Feinberg of the UNC Translational Pathology Laboratory performed 
Immunohistochemistry.  Briefly, antigen retrieval was performed with Bond-Epitope 
Retrieval solution (Leica) for 30 min at 100°.  Slides were next incubated in either 
rabbit anti-phospho-cofilin 1:300 (Cell Signaling Technology) or mouse monoclonal 
anti-CD31 1:200 (Leica Microsystems) primary antibodies for 1 hr.  Rabbit or mouse 
secondary antibodies were then applied for 1 hr and detected by the Bond Polymer 
Refined Detection System. Tissue immunofluorescence was carried out after 
incubation with an antibody against CD31 (1:200), which generated an endothelial 
cell mask. CD31 was then detected by a HRP linked to Bond Polymer. Following 
CD31 staining, an anti-phospho-cofilin antibody (1:300) was added. A goat anti-
mouse-HRP (Envision+) secondary antibody was then added to the samples and 
Cy5-tyramide (PerkinElmer) was used for the fluorescence. Slides were then cover 
slipped and preserved with ProLong gold antifade reagent (Molecular Probes) with 
DAPI for nuclear staining. Slides were then quantified through AQUA image analysis.  
Briefly, an Aperio FL microscope (Aperio) integrated with HistoRx AQUA scan 
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technology (HistoRx) made a 20x scan of each slide for the DAPI, CY3, and CY5 
channels. These spectrum of these scanned images were then analyzed using the 
AQUA algorithm following provided instructions (AQUAnalysisTM Aperio Edition Rev. 
1.0, CDN0044, HistoRx). 
 
Image densitometry analysis 
 Densitometry for western blotting was obtained using ImageJ (NIH) normalized 
to Erk1/2 loading control pixel density. 
 
Multiplexed inhibitor beads coupled with mass spectrometry  
 MIB/MS experiments were performed as described previously by Duncan et al.  
Briefly, cells were lysed in low salt buffer (LSB) comprising 0.5% Triton X-100, 50 
mM HEPES, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 10mM sodium fluoride, 2.5 
mM sodium orthovanadate, 1X protease inhibitor cocktail (Roche), and 1% of the 
phosphatase inhibitor cocktails 2 and 3 (Sigma). Protein kinases were isolated by 
flowing lysates over columns containing the following kinase inhibitors that were 
covalently conjugated to sepharose beads: Bisindoylmaleimide-X, SB203580, 
Lapatinib, Dasatinib, Purvalanol B, VI16832, PP58, AKT inhibitor, and Shokat.  
Inhibitors were synthesized by Dr. Jian Jin (UNC) and covalently attached to 
sepharose beads by Deborah Grangier (UNC). Kinases bound to the inhibitor beads 
were washed with LSB followed by high salt buffer (HSB) containing 50 mM HEPES, 
0.5% Triton X-100, 1 mM EGTA, 1 mM EDTA, 1 M NaCl and then washed with 0.1% 
SDS, and eluted in 0.5% SDS after boiling for 5 minutes. Standard 
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methanol/chloroform extraction methodlogy was utilized for the purification of 
proteins, followed by resuspension in 50 mM HEPES and overnight trypsin (Roche) 
digestion at 37 °C.  Samples were then iTRAQ labeled for two hours at room 
temperature and cleaned with PepClean columns (Pierce).  Peptides were subjected 
to liquid chromatography and spotted based on hydrophobicity with a Tempo 
LC/MALDI (Applied Biosystems). Spotted plates were loaded on a MALDI TOF/TOF 
5800 (ABSCIEX) and MS/MS spectral data were acquired. Peptides were identified 
by the Protein Pilot Software (ABSCIEX), which links to the UniProtKB/Swiss-Prot 
online database.  The Pro Group algorithm was utilized for specific peptide 
quantitation and the subsequent ratios were corrected for bias.  Individual peptide 
spectral mass accuracy was verified manually.  The MIB/MS experiments were 
performed in collaboration with Dr. Christopher Dibble and Rachel Reuther. 
 
Sequence analysis of human CCM samples 
 CCM lesions were obtained from the Angioma Alliance CCM DNA and Tissue 
Bank (www.angiomaalliance.org). Surgically resected familial patient lesions were 
confirmed by radiographic analysis by clinicians. The mutation of each CCM lesion 
was determined by screening patient peripheral blood mononucleocyte DNA with 
specific CCM PCR probes, which is standard methodology for for genetic diagnosis 
of CCM patient mutations. 
 
Statistical significance  
 Statistical significance was determined through a paired Student's t-test (two-
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tailed) and the data represent the average of at least 2 independent biological 
experiments. 
 
Tube formation assays 
 Tube formation assays were conducted by seeding 8.5 × 105 cells on 310 µl of 
Matrigel (BD Biosciences) for at least 15 hours.  Tube-like structures were fixed in 
4% para-formaldehyde for 15 min permeabilized with .1% Triton X100/PBS for 10 
min.  Actin was stained with rhodamine-phalloidin (Invitrogen), and nuclei were 
stained with Hoechst dye (Sigma). Quantitative image analysis was performed using 
a Cellomics ArrayScan (Thermo Scientific) or  the BD Pathway (BD Biosciences). 
The mean tube area was automatically quantified utilizing Cellomics Arrayscan 
software.  
 
Western blotting 
 Total cell lysates were prepared by washing cell cultures twice with ice cold 
PBS and incubating the dishes with lysis buffer containing 50 mM Tris (pH 8.0), 150 
mM NaCl, 1% Triton X-100, .5% sodium deoxycholate and .1% SDS supplemented 
with 1x protease inhibitor tablets (Roche) on ice for 10 min followed by aggressive 
scrapping. 30 µg of total protein lysate was separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes were probed with anti-Erk2, 
anti-RhoA sc-22, anti-BMX (Santa Cruz), anti-cofilin, anti-phospho-cofilin, anti-LIMK1, 
anti-phospho- LIMK1/2, and anti-Tie2 (Cell Signaling Technology) antibodies.  All 
mouse or rabbit secondaries were from Jackson ImmunoResearch. Cells were 
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incubated with the indicated with the Rock inhibitors Fasudil or Y-27632 
(CellBiochem) pharmacological agents at indicated concentrations for 1 hr before 
lysis. 
 
Chapter IV 
 
Cell culture 
 MEECs or Huvecs were subcultured and CCM1, -2, -3, Smurf1, Smurf2, and 
Cullin3 knock down cells were generated exactly as described for Chapter III. 
 
Immunoprecipitation assays 
 GFP tagged CCM1, CCM2, and CCM2 F217A, HA tagged CCM2 and Flag 
tagged Smurf1 or Flag tagged Smurf2 were co-expressed in HEK 293T cells for 16 
hrs using lipofectamine and reagent plus transfection following manufacturer 
instructions (Invitrogen).  Cells were lysed in lysis buffer containing 50 mM Tris (pH 
8.0), 150 mM NaCl, 1% Triton X-100, 5 mM MgCl2 supplemented with 1x protease 
inhibitor tablets (Roche) on ice for 10 min followed by aggressive scrapping.  
Insoluble membrane fractions were spun down for 5 minutes at 4°C.  Approximately 
500 µg of cell lysate was used for immunoprecipitation with 1 µg of anti-Flag M5 
antibody (Sigma) for 1 hour with gently rotation at 4°C.  A total of 25 µl of a 50% 
slurry of Protein G sepharose beads were then added to each of the samples for 1hr 
with gentle rotation at 4°C. Protein antibody immunoprecipates were eluted by 
boiling in SDS sample buffer for 5 minutes at 100°C.      
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Rhotekin-RBD active pull down assays: 
 Recombinant GST tagged RBD (gift from Dr. Keith Burridge) was used for the 
assessment of activated GTP bound RhoA.  GST-RBD was purified using 
glutathione sepharose resin from 1 L cultures of BL-21 Gold E. coli bacteria 
transformed with pGEX GST-RBD.  Cell cultures were washed twice with ice cold 
PBS and lysed on ice in a cold room with a lysis buffer containing 50 mM Tris (pH 
8.0), 150 mM NaCl, 1% Triton X-100, .5% sodium deoxycholate, .1% SDS, 10mM 
MgCl2 and supplemented with 1x protease inhibitor (Roche).  Lysates were 
incubated with either control glutathione sepharose beads or GST-RBD beads for 25 
minutes with gentle rotation at 4°C.  GTP Bound RhoA beads were washed 3x with 1 
mL of wash buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 
5mM MgCl2 supplemented with 1x protease inhibitor (Roche).  GTP RhoA bound to 
GST RBD was eluted from the glutathione beads by boiling in SDS sample buffer for 
5 minutes.  Input total cell lysate and pull down samples were then separated by 
SDS PAGE, transferred to nitrocellulose membranes, and blotted using anti-RhoA, 
anti-Erk2, or anti-Ubiquitin antibodies (Santa Cruz) with the corresponding 
secondary antibody.   
 
Statistical significance  
 Statistical significance was calculated using a paired two-tailed Student's t-test. 
Data represented the mean of at least 2 biologically independent experiments. 
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Densitometry, Immunofluorescence, Tube formation assays, and Western blotting.  
 These methods were carried out exactly as described for chapter III.   
 
Chapter V 
Cellular proliferation assays 
Cells were seeded in triplicate in 96 well tissue culture plates. The CellTiter-
Glo reagent was incubated on cells per manufacturer instructions (Promega).  
Luminescence was read and quantified on a PHERAstar plate reader (BMG 
Labtech).  
 
Endothelial differentiation 
Confluent hESC cultures were scored and lifted for the generation of EBs (D-
1).  EBs were generated in EB generation media constituting the following 
ingredients: DMEM/F12 (Gibco) supplemented with knock out serum replacement 
(Gibco), .1 mM β-mercaptoethanol, 1X non-essential amino acids, 1X 
penicillin/streptomycin, and 1X L-Glutamine.  Media was changed and only formed 
EBs were kept.  BMP4 (D0), Activin A (D1), and bFGF (D2) were added sequentially 
each day (D0-D2).  On Day 4 the EBs were spun and resuspended in fresh EB 
generation media supplemented with VEGF-A, bFGF, and BMP4; EBs were plated 
out on a regular tissue culture plate coated with 1:120 diluted matrigel. From days 7 
to 14, cells were cultured in EB generation media supplemented with VEGF-A, bFGF, 
and SB431542 with media renewal every 48hours.  On day 14, CD31+ endothelial 
cells were separated from differentiating cultures. Cells were trypsinized and 
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incubated with CD31 specific magnetic microbeads and isolated over two MS or LS 
columns per manufacturer instructions (Miltenyi Biotec).  Isolated ECs were 
maintained in this media with renewal every 48 hours.  BMP4 (Peprotech), VEGF-A 
(Shenandoah Biotechnology), bFGF (Peprotech), Activin A (Peprotech), and 
SB431542 (Tocris) were used at 20 ng/mL, 50 ng/mL, 10 ng/mL, 10 ng/mL, and 10 
µM, respectively. 
 
Establishing and passaging EPC-ECs 
 Six well plates were coated with 50 µg/mL of rat type I collagen 
suspended in .02N acetic acid 1 hr prior to plating PBMCs.  This solution was 
washed 2x from the plates with HBSS and PBMCs (approximately 20x 10^6) were 
plated in EGM-2C at 37°C.  Media was renewed every 72 hrs for 7 days, after which 
it was renewed every 48 hours until colonies were visualized.  Typically colonies of 
ECs appeared after 4 weeks and were passaged when covering between 30 and 
50% of the dish.  These EP-ECs were passaged at 95% confluency and were 
cultured at low split ratios to maintain a high confluency. 
 
Flow cytometry 
All flow cytometry was done in the UNC Flow Cytometry Core Facility using 
Beckman CyAn instruments.  At least 1e^4 cells were analyzed after being stained 
with isotype specific control antibodies or epitope specific antibodies conjugated to 
either PE, APC, or FITC; all flow cytometry antibodies were purchased from BD 
biosciences. 
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Human embryonic stem cell culture and CCM protein knock down 
The H1, H7, and H9 hESC lines were grown in the UNC Human Embryonic 
Stem Cell core facility under supervision from the University Embryonic Stem Cell 
Research Oversight Committee (ESCRO).  hESCs were maintained as colonies 
grown on standard tissue culture dishes coated with 1:120 diluted hESC-qualified 
matrigel (BD biosciences) in mTeSR1 growth media (Stem Cell Technologies).  
hESCs were fed daily and split every 3-5 days once proper density was reached.  
CCM proteins were knocked down using the shRNAs described in chapter 3. Briefly, 
cells 48 hours following the previous passage were infected with viral particles at a 
ratio of 1:1, 2:1, and 3:1 viral producing cells seeded to host cells (i.e. 1, 2, or 3 
volumes of virus generated from a 293T producing plate was incubated on the same 
size host cell plate).  Clones were passaged after puromycin selection, and knock 
down efficiency was determined by qRT-PCR. 
 
iPS cell derivation and culture 
Retrovirus encoding Oct4, Sox2, KLF4, and cMyc was packaged as 
previously described utilizing PMX vectors purchased from Addgene (Yamanaka ref).  
Infected EPC ECs, Huvecs, or MRC5 fibroblasts were seeded on MEFs in iPS cell 
induction media constituting the following ingredients: DMEM/F12 (Gibco) 
supplemented with knock out serum replacement (Gibco), .1 mM β-mercaptoethanol, 
1X non-essential amino acids, 1X penicillin/streptomycin, 1X L-Glutamine, and 10 
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ng/mL bFGF.  Colonies were picked based upon similar morphology to hESCs, 
expanded on MEF feeders and then cultured on matrigel as described for hESCs. 
 
Neural differentiation 
EBs were formed as described for endothelial differentiation in EB generation 
media for 4 days.  EBs were then placed in a new petri dish in neural induction 
media constituting the following ingredients: DMEM-F12, 1X N2 supplement (Gibco), 
1X penicillin/streptomycin (Gibco), 1x non-essential amino acids (Gibco), 10 µg/mL 
heparin (Sigma), 10 ng/mL bFGF (Peprotech).  EBs were seeded on fibronectin 
coated cell culture dishes and neural induction media was changed every day.  
Neural rosette-like structures were observed on day 14 and used for pan-neural 
marker stanings.  
 
PBMC isolation 
The UNC Institutional Review Board approved the blood draws and the use of 
human blood (IRB# 10-1595).  Normal patient peripheral blood was obtained using 
standard phlebotomy techniques the anti-coagulant sodium citrate.  PBMCs were 
obtained by diluting 80 mL of peripheral blood in half with HBSS (Gibco) 
containing .5% BSA/1 mM EDTA.   This blood solution was then quickly but gently 
layered on an equal volume of Histopaque-1077 (Sigma) in 50 mL polypropylene 
tubes. Before separation occurred, the tubes were spun at room temperature (RT) 
for 30 min at 400 x G.  Following centrifugation, the plasma layer was removed and 
the white/opaque layer containing PBMCs was collected in new tubes and total 
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volume was brought to 50 mL with 12% FBS EGM-2 (Lonza) containing 12% FBS 
(Atlantic Biologicals) and an additional 1x antibiotic/antimycotic solution (Gibco) 
(denoted as EGM-2EP).  The tubes containing the PBMCs were centrifugated at RT 
15 minutes at 400 x G.  Pellets were combined, washed twice to remove residual 
platelets, and counted for plating.    
 
Statistical significance  
 Statistical significance was calculated using a paired two-tailed Student's t-test. 
Data represented the mean of at least 2 biologically independent experiments. 
Teratoma Formation 
Mouse teratoma studies were completed under approved IACUC protocols. 
Pluripotent cells were disassociated into a single cell suspension with .03% EDTA 
(Sigma).  BALB/c nude mice were injected on both flanks with 1e^6 cells suspended 
in a 50% matrigel/PBS solution containing 10 µM ROCK inhibitor (Tocris).  Mice 
were carefully monitored, and tumors were removed before they reached 1 cm3.  
Tumors were formalin fixed and prepared for hematoxylin and eosin histological 
staining by the UNC Animal Histopathology Core Facility.  
 
Densitometry, immunoflourescence, tube formation assays, and Western blotting.  
 These methods were carried out exactly as described for Chapter III. 
 
 
 
 
 
III. Global kinome profiling of deregulated kinases in CCM 
 
Introduction: 
The signaling mechanisms driving CCM lesion development remain 
incompletely characterized.  It is likely that deregulated signaling cascades are 
driving the common biochemical and phenotypic abnormalities observed after the 
loss of any of the three CCM proteins.  Current studies have indicated that the CCM 
protein complex regulates the actin cytoskeleton, which helps maintain vascular 
homeostasis [4, 39, 168].  The CCM proteins form a ternary complex, and shRNA 
knock down of CCM1, -2 or -3 increases active and total RhoA levels in ECs [4, 74].  
Therefore, a major focus in CCM research has been to elucidate potential 
mechanisms driving deregulated RhoA signaling.   
RhoA regulates the actin cytoskeleton by activating its downstream effectors 
mammalian diaphanous (mDia) and Rho kinase (ROCK) [118]. Recent studies have 
demonstrated that loss of CCM proteins increases ROCK activity and phospho-
MLC2, which negatively effects tube forming ability, invasion, and monolayer stability 
[4, 7].  Importantly, small molecule inhibition of RhoA or ROCK rescues both the 
biochemical and cellular phenotypes.  These data suggest that increased ROCK 
activity downstream of RhoA stabilizes the actin cytoskeleton and drives CCM 
phenotypes.  As a therapeutic strategy, targeting RhoA and ROCK signaling is 
promising as several ROCK inhibitors are being actively developed, and the ROCK 
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inhibitor Fasudil has been used to treat cerebral vasospasm in Japan for two 
decades [169, 170].  
In lieu of this progress, the deregulation of additional kinases in CCM remains 
largely unknown.  There are at least 130 kinase inhibitors currently in clinical trials, 
and the kinome as a whole is understudied in CCM signaling biology. Thus, the 
discovery of additional kinases that can be targeted may be a useful therapeutic 
avenue for the treatment of CCM.  Examining the expression or activity of kinases 
typically requires an enrichment procedure, such as antibody-mediated 
immunoprecipitation followed by western blotting or mass spectrometry.  This 
strategy is only useful for those kinases for which good antibodies are available, and 
the assessment of activation status requires the availability of phosphorylation state 
specific antibodies.  Thus, an approach that allows for the identification of many 
kinases across all families of the kinome would represent an important method for 
obtaining a profile of deregulated kinase networks that may drive the CCM 
phenotype.  To address this need, kinase inhibitors immobilized on bead resin 
technologies have been developed [171, 172].  These inhibitors selectively bind to 
the activated form of the kinase, and can be used to pull down active kinases, which 
then can be identified by quantitative mass spectrometry.  This type of approach has 
been used to identify differentially phosphorylated kinases and novel protein 
phosphorylation sites during cell cycle regulation with great precision [171].  Our lab 
expanded on this approach with multiplexed kinase inhibitor beads coupled with 
quantitative mass spectrometry (MIB/MS) to elucidate the kinome reprogramming 
following Mek inhibition in triple negative breast cancer.  These inhibitors are both 
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selective (Bisindoylmaleimide-X, SB203580, Dasatinib, Lapatinib, AKT, and Shokat) 
and broad (PP58, VI16832, and Purvalanol B). This proteomic kinome approach led 
to the discovery of kinases that were over activated upon Mek inhibition and the 
rational design of a new combinatorial therapeutic for Mek resistant cells and tumors 
[173].  Therefore, understanding the kinome signaling mechanisms involved in 
driving CCM lesion formation could be instrumental in designing a single agent or 
combinatorial agent therapy in CCM.       
In this study, we utilized MIB/MS technology to discover potential novel 
kinase signaling networks involved in CCM.  For these experiments, we used both 
Huvec and MEEC cell culture systems with stable shRNA knock down of the CCM 
proteins.  We detected LIMK downstream of RhoA that was hyperactivated in CCM 
deficient ECs. We demonstrated that LIMK1 was both phosphorylated and 
overactive in CCM1, -2, and -3 deficient endothelial cells from both mouse and 
human and surgically resected patient lesions.  These data have validated LIMK as 
a therapeutic target and show for the first time that LIMK signaling resulting in the 
inactivation of the actin depolymerizing factor (ADF) cofilin gives rise to CCM 
phenotypes.  We further show that endothelial regulators such as, Tie2, TGF-β 
receptor, and BMX/ETK kinases are deregulated following loss of CCM proteins.    
This work was done in collaboration with Dr. Christopher Dibble who validated 
in vitro LIMK signaling and Rachel Reuther who assisted in MIB/MS assay 
development.    
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Results 
Kinome profiling of CCM deficient human and mouse endothelial cells. 
There is relatively little known about the CCM protein specific kinome 
regulation and how that contributes to the pathology of CCM.  To address this 
problem, we utilized MIB/MS technology to discover novel kinases that are  over or 
under represented in CCM2 protein deficient cells.  For a typical experiment, cells 
were grown following knock down for a period of 10 to 14 days to obtain the later 
and more stable changes following CCM protein loss.  Knock down was validated by 
q-RT-PCR and the CCM phenotype was validated by cellular stress formation 
assays (Fig 3.0).  Knock down data for all cell lines is provided (Fig 3.20 A-D).  The 
knock down cells were then lysed, and the whole cell protein fraction was flowed 
over multiplexed kinase inhibitor beads, purified, and peptides were quantified (Fig 
3.1).  We identified 169 kinases covering approximately 32% of the known human 
kinome that were either over represented or under represented in CCM2 deficient 
endothelial cells (Fig 3.2 A).   
We were able to validate this approach by detecting kinases previously 
implicated in the signaling biology of CCM, such as ROCK1, ROCK2, STK24, 
STK25, Tie2, MEKK3, MKK3, and TGF beta (Fig 3.2 B).  As a proof of concept, we 
found that ROCK1, which is a widely accepted driver of the CCM phenotype, was 
also over represented.  TGFR1 (TGF-β receptor 1) was found to be over 
represented consistently across experiments.  This result is inline with a recent study 
that demonstrated that elevated TGF-β signaling is involved in promoting EndMT in 
CCM1 deficient cells, suggesting that CCM2 deficient cells may be undergoing a 
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similar process [69]. We also observed over representation of the Tie2 receptor, 
which is a specific endothelial receptor tyrosine kinase, which has been shown to be 
overexpressed in CCM patient lesions and in cells isolated from patient lesions [174].  
Lastly, our laboratory reported that CCM2 (OSM) functions to increase the activity of 
M3K3 leading to increased MP2K3 phosphorylation and p38 activation [70].  
Consistent with this result, we observed a decrease in M3K3 binding to the inhibitor 
beads following the loss of CCM2 protein (Fig 3.2 B).  In addition, approximately 
1/3rd of the quantified kinases were found to regulate the actin cytoskeleton after 
Ingenuity Pathway Analysis.  This result is in line with the field as there is a general 
consensus among all studies that CCM proteins regulate endothelial cell cytoskeletal 
stability (Fig 3.3).  Overall, these data suggest that MIB/MS technology can be used 
as a consistent method for probing novel kinase networks in CCM. 
Our results showed that approximately 30% of the detected kinases were 
conserved across mouse and human (Fig 3.4).  CCM phenotypes are rescued with 
the inhibition of ROCK; therefore, we treated MEEC CCM2 stable knock down cells 
with the Y-27632 ROCK inhibitor for 48 hours.  After proteomic analysis, we 
discovered that only a few of the kinases other than ROCK itself were oppositely 
affected either negatively or positively by Y-27632 (highlighted in red boxes).  This 
finding suggests that the majority of kinases were not greatly affected by ROCK 
inhibition, and these kinases maybe some how acting upstream or independently of 
ROCK in CCM2 deficient ECs (Fig 3.4).   
We next wanted to determine if CCM1 and CCM3 deficient ECs had similar 
kinase profiles to that of CCM2 deficient ECs.  After completing MIB/MS analysis 
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over multiple experiments with CCM1 and CCM3 deficient Huvecs, we similarly 
achieved 30% coverage of the human kinome with all kinase families represented 
(Fig 3.5 and 3.6).  Clustering kinases based upon shared kinases that were either 
over or under represented revealed differences in the conserved kinases between 
CCM1/CCM2, CCM1/CCM3, or CCM2/CCM3 (Fig. 3.7, 3.8, and 3.9).  The number 
of deregulated kinases was similar both in total number of changed kinases and in 
the number of under and over represented kinases with more under represented 
kinases detected than over represented kinases (Fig. 3.10).  The total number of 
conserved kinases between CCM1, -2, and -3 deficient Huvecs was significantly 
lower with 62 similarly represented kinases.  Some of these overlapping kinases for 
CCM1, -2, and -3 deficient ECs are important mediators of RhoA signaling or 
regulate endothelial function (Fig 3.11).  We detected ROCK1 and ROCK2 in all 
Huvec samples with CCM2 cells having a strong increase in ROCK1 representation 
and CCM3 cells having a lesser increase in ROCK2 representation.  ROCK2 is 
thought to be more brain endothelial cell specific; however, the two isoforms are 
highly conserved and specific isoform studies involved in endothelial function have 
not been carried out.  Surprisingly, CCM1 deficient cells had decreased levels of 
both ROCK1 and ROCK2.  This finding is unexpected because CCM1 deficient cells 
have a strong induction of stress fibers upon CCM protein loss and those stress 
fibers can be rescued following ROCK inhibition (Fig 3.0).  Furthermore, loss of 
human CCM proteins consistently increases total and activated RhoA levels.  It is 
possible that the loss of CCM1 potentiates other RhoA mediated drivers for the CCM 
phenotype, such as mDia1 and ROCK inhibition is sufficient to overcome these 
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parallel events.  In addition to the RhoA effector ROCK, we were able to detect the 
RhoA effector PKN1, which was under represented in CCM1, -2, and -3 deficient 
Huvecs (Fig 3.10).  PKN1 binds to and is activated by RhoA and has further been 
shown to perpetuate RhoA signaling by preventing the endogenous GAP activity of 
RhoA [175].  A closely related family member PKN3 has been shown attenuate F-
actin stress fiber formation and alters VEcadherin localization following TNF-α 
stimulation in Huvecs; it is unclear whether these results were dependent upon 
RhoA/ROCK signaling [176].  Therefore the interplay of the PKN family members 
and RhoA signaling could represent an unknown mechanism behind CCM 
phenotypes.   
The most relevant kinase that we discovered, which was both over 
represented and intrinsically linked to F-actin formation, downstream of RhoA was 
LIM kinase 1 (LIMK1).  LIMK could represent an important targetable kinase in CCM, 
as LIMK inhibitors are being developed and have shown promising results in pre-
clinical mouse breast cancer models [177, 178].  Interestingly, only LIMK1 and not 
LIMK2 was over represented in CCM2 deficient endothelial cells from both mouse 
and human, which was decreased after ROCK inhibition (Fig 3.4).  Therefore, we 
focused our validation studies on LIMK1.  The activation state and not the 
expression of LIMK1 was effected in CCM1, -2, and -3 knock down ECs as only the 
phosphorylated form of LIMK1 was increased (Fig 3.12A).  Furthermore, the 
activation of LIMK1 was placed downstream of RhoA/ROCK signaling because 
ROCK inhibition by Fasudil decreased the activity of LIMK (Fig 3.12B).  
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LIMK and cofilin phosphorylation decreases tube formation rescuable by LIMK1 
knockdown  
The role of LIMK as a driver of CCM phenotypes was interrogated by 
generating stable LIMK and CCM protein double knock down ECs.  The ability of 
these cells to form tube-like structures was compared to Plko.1 control and CCM 
single knock down ECs.  Knock down of LIMK1 with two independent shRNAs 
resulted in a large decrease in the phosphorylation levels of LIMK and cofilin (Fig 
3.13A and B).  CCM2/LIMK double knock down cells had normal levels of pMLC2 
when compared to controls, which indicates that LIMK is selectively inhibiting cofilin 
(Fig 3.13C).  We have previously published that tube formation defects can be 
rescued by CCM protein knock down in ECs through the inhibition of ROCK (Fig 
3.14A) [4, 5].  Importantly, we now show that the knock down of LIMK1 in CCM 
protein deficient ECs is sufficient to rescue tube-like structures similar to ROCK 
inhibition.  Examining the tube formation process across time points reveals that 
CCM2 knock down cells that have been treated with either Y27632 or LIMK1 knock 
down begin forming tubes after 4 hours, which is identical to control Plko.1 cells.  
These morphological changes are in contrast to untreated CCM2 knock down cells, 
which maintain a rounded and immobile phenotype, indicating defects in the actin 
cytoskeleton consistent with the observed increases in pMLC2 and pCofilin.  These 
data suggest that the LIMK1 activation and subsequent phosphorylation of cofilin is 
important for CCM pathophysiology.  Taken together, decreasing actin 
depolymerization increases total F-actin, which is required for the cross linking of 
MLC and actin.  When LIMK1 is knocked down in the absence of CCM proteins, the 
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amount of phospho-cofilin decreases and actin is again severed.  The levels of 
pMLC2 remain high; however, there is no functional effect because there is not any 
F-actin for MLC2 to cross-link.  Thus, targeting LIMK may represent a more specific 
therapeutic avenue than inhibiting ROCK with several non-toxic LIMK inhibitors that 
decrease pCofilin levels [177, 179].   
 
Phospho-cofilin levels are increased in surgically resected human CCM lesions 
Previously, it has been shown that pMLC2 levels are increased in human 
CCM lesions [7].  Therefore, we sought to determine if pCofilin might also be active 
in human surgically resected CCM lesions.  We first validated a monoclonal antibody 
specific to pCofilin through an immunohistological quantitation methodology known 
as Advanced QUantitative Analysis (AQUA), which scores immunoflourescent 
protein expression from tissues slides [180].  This validation was accomplished by 
placing stable CCM knock down MEECs in paraffin and processing them identically 
to tissue sections.  After staining, we observed a significant increase in pCofilin 
staining levels in CCM protein deficient MEECs, consistent with our immunoblotting 
data (Fig. 3.15A and B).  Phospho-cofilin levels were then analyzed in surgically 
resected lesions from CCM patients that have confirmed gene mutations in ccm1, -2, 
or -3 (Fig. 3.15F). Immunohistochemical analysis shows a dark brown staining only 
in CCM lesions and not in normal brain capillaries from non-CCM patients (Fig 
3.15C).  CCM phenotypes are thought to be endothelial cell autonomous; therefore, 
we utilized an endothelial specific CD31 (Pecam1) mask to assess whether the 
elevated pCofilin levels were restricted to the endothelium by immunoflourescence 
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[181].  Accordingly, we observed a high overlay of pCofilin signal in the endothelial 
cell monolayer, which was not observed in normal brain tissues. The levels of this 
staining were between 4 and 10 fold higher in CCM patients after AQUA analysis 
(Fig 3.15 E).  These results are similar to previous immunohistochemical studies on 
pMLC2 expression in CCM lesions and provide additional evidence of aberrant 
ROCK signaling in the ECs from CCM lesions [7].  Overall, these data show for the 
first time that pCofilin is a unique biomarker for CCM patient samples and suggest 
that LIMK is a physiologically relevant kinase involved in CCM pathophysiology. 
 
CCM proteins regulate the expression of Tie2 and BMX upstream of ROCK 
We next validated some of the other kinases that we identified by MIB/MS 
profiling that have important functions in either regulating RhoA or endothelial cell 
function that were conserved among CCM1, -2, and -3 knock down cells. (Fig 3.11).  
The Tie2 angiopoietin receptor is specifically expressed in the endothelium and is an 
important regulator of endothelial activation, quiescence, and is activated by either 
angiopoietin 1 or 2 (Ang1/2).  These two ligands compete with each other for binding 
to Tie2.  Ang1 promotes vascular quiescence through the strong agonist activity of 
Tie2, which increases Notch1 signaling, where as Ang2 acts as a competitive 
antagonist of Ang1 leading to decreased Notch1 signals [182-184].  The net result is 
Ang1 and Ang2 promote a stable impermeable vasculature or a hyperpermeable 
activated vasculature, respectively.  Furthermore, high levels of Ang2 decrease 
pericyte recruitment to endothelial cells [185].  The effects of altered vascular 
quiescence, permeability, and mural cell recruitment that also occurs through altered 
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Tie2 and Notch signaling are all shared phenotypes with CCM1 -2, or -3 deficient 
ECs. Currently, there are not any reliable activation state specific phospho-tyrosine 
antibodies for Tie-2.  Therefore, we first assessed Tie2 expression.  We find that 
both Tie2 protein levels and message levels are increased significantly after CCM1, 
-2, and -3 protein loss (3.16 A and B).  This increased expression appears to be 
upstream of ROCK signaling as ROCK inhibition did not attenuate the expression of 
Tie2 (Fig 3.17).  Tie2 through Ang1 binding is thought to promote endothelial cell 
quiescence; therefore, a more detailed study into whether Tie2 is being activated by 
either Ang1 or Ang2 is needed.  
In contrast to Tie2, we observed a conserved under representation of the 
BMX/TEC non-receptor tyrosine protein kinase (Fig 3.16 C).  This kinase is directly 
activated by Tie2 and is essential for proper in vitro tube formation and hind-limb 
ischemia recovery in mice through its functions in regulating RhoA activity [186, 187].  
BMX may be relevant to CCM biology through its ability to activate RhoA and 
localize RhoA to the membrane by disrupting the interaction of RhoA and Rho GDIs 
[188].  Similarly to Tie2, we noted a marked decrease in protein and mRNA levels in 
CCM deficient ECs (Fig 3.16 D).  The expression defects were not significantly 
rescued with ROCK inhibition (Fig 3.17).  These results are somewhat obfuscating in 
that CCM deficient cells have greatly increased RhoA activity levels. It would be 
expected that if BMX were a driver of the CCM phenotype, it would also be strongly 
activated. However, our data by MIB/MS, qRT-PCR, and western blotting show a 
strong decrease in BMX expression (Fig 3.10, 3.16 C and D).  These data suggest 
that CCM deficient endothelial cells maybe employing some form of compensation 
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mechanisms to overcome the increased RhoA activation.  This hypothesis is in 
agreement with the over representation of Tie2 binding to our inhibitor beads, which 
should promote endothelial cell quiescence.  Therefore, a comprehensive 
mechanism that includes Tie2 and BMX may exist to carefully regulate RhoA activity 
in vascular homeostasis, which is insufficient to overcome the RhoA overactivation 
in CCM protein deficient cells.  Identifying additional RhoA regulatory mechanisms 
that are changed in CCM protein deficient cells will determine whether additional 
pharmacologically relevant targets exist that can be exploited to restore proper RhoA 
levels.   
 
Discussion 
This study has uncovered a plethora of kinases that are deregulated after the 
loss of CCM proteins in a non-biased way.  Because there are many kinase 
inhibitors that are FDA approved or are in clinical trials, this information will be a 
valuable resource for the scientific community to establish new potential targetable 
kinases.  To this extent, we have both provided an independent validation of kinases 
already shown to be involved in CCM and added to this list of validated kinases.  We 
show that the LIMK/cofilin arm of the RhoA/ROCK signaling pathway is involved in 
CCM phenotypes.  The over activation of LIMK leads to increased phosphorylated 
coflin and increased actin stability [189, 190].  This LIMK/cofilin pathway may 
represent the dominant acting portion of the RhoA/ROCK pathway.  Previously, 
pMLC2 has been thought to be the only functional surrogate marker for CCM.  
However, increased cofilin function through shRNA mediated knock down of LIMK is 
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sufficient to restore endothelial cell functionality in CCM protein deficient ECs even 
with elevated pMLC2 levels.  This result suggests that LIMK/cofilin maybe dominant 
over just pMLC alone in causing CCM phenotypes.  Inhibition of MLC phosphatase 
(MLCP) has been shown to increase actin stress fibers [191, 192]. Therefore, it 
would be interesting to use a MLCP inhibitor, such as Ruthenium Red, to determine 
if increasing pMLC2 levels is sufficient to generate CCM phenotypes [193].  These 
data raise important observations on the relative contributions of actin stabilization 
through LIMK activation and actin myosin contractility promoted by increased ROCK 
activation.  Relevant to in vivo pathology, this study further shows that CCM patient 
lesions have elevated phospho-cofilin.  This finding in conjunction with prior work 
establishing increased pMLC2 in patient lesions corroborates how the RhoA/ROCK 
signaling pathway is physiologically relevant.  Thus, through an unbiased approach 
our work has established that LIMK is a physiologically relevant kinase for 
therapeutic intervention.  This basic discovery could be translated to the clinic 
relatively rapidly with pre-clinical LIMK inhibitors being developed for the treatment 
of breast cancer. 
Our MIB/MS proteomic data further identified kinases that are known to be 
important in endothelial function.  The Tie2 receptor has been shown to be elevated 
in certain CCM patient lesions and cells isolated from those lesions and have been 
implicated in other vascular malformations [174, 194, 195].  Furthermore the 
opposing function of Ang2 to Ang1 results in an increased expression of the Tie2 
receptor [196].  This result is consistent with our increased Tie2 expression data.  
Therefore, it will be of interest to determine the relative contributions of Ang1 and 
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Ang2 on Tie2 in CCM protein deficient ECs.  Inflammatory cytokine expression has 
been reported to increase Tie2 expression and is characteristic of CCM lesions [134, 
197].  Indeed, by MIB/MS we have detected a large decrease in both IKKA and IKKB 
representation, which regulate the important inflammatory regulator NF-κB (Fig 3.10).  
The elucidation of these signaling nodes could provide a mechanistic insight into the 
Tie2 expression changes we observe.  BMX and TGF-β receptors were further 
shown to be deregulated by MIB/MS profiling.  These kinases have well documented 
important functions in regulating the activation state of the endothelium and RhoA.  
Thus, future work will elucidate how these kinases are regulated and how they 
contribute to the CCM phenotypes.  Overall, our data gathered by MIB/MS profiling 
represents the first broad scale examination of the kinome in CCM, and future work 
will reveal additional therapeutically relevant kinases for disease intervention
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Figure 3.0: CCM protein deficient Huvecs have increased stress fiber 
formation.  Example validation of the known stress fiber CCM phenotype following 
loss of CCM1, -2, or -3.  Stress fibers were rescued by ROCK inhibition by Y-27632 
(images taken at 40x magnification).  Bottom panel shows shRNA knock down 
efficiency (N=3 CCM1 and CCM3; N=4 CCM2 and Plko.1).  
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Figure 3.1: Strategy for assessing global kinome activation status in CCM 
protein deficient cell culture.  Viral particles are generated in 293T producing cells 
and incubated on normal healthy endothelial cells.  Stable knock down cultures are 
verified by qRT-PCR and maintained for at least 10-14 days.  Cell cultures are lysed, 
proteins extracted, and flowed over multiplexed kinase inhibitor bead columns.  The 
MS/MS spectra corresponding to peptides are quantified after running on a MALDI 
TOF/TOF 5800.  
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Figure 3.2: CCM2 protein loss affects the kinome. Stable shRNA knock down 
was achieved in Huvecs and the kinome was profiled. A). Altered kinase activation 
or expression was detected across all major kinase families.  B). Previously 
identified kinases in CCM were also detected.  Bars to the right of center and left of 
center indicate kinases over or under represented when compared to control, 
respectively. No bar indicates a kinase detected but unchanged compared to control.  
Error bars represent the average of at least two experiments where a kinase was 
quantified; four independent experiments were conducted. 
A.	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Figure 3.3: Cytoskeletal regulating kinases are both over and under 
represented.  Ingenuity pathway analysis was used to determine, which quantified 
kinases had direct effects in modulating the actin cytoskeleton.  Importantly, the 
kinases LIMK1 and ROCK1, which function downstream of RhoA, were among the 
highest. Error bars represent the average of at least two experiments where a kinase 
was quantified; four independent experiments were conducted 
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Figure 3.4:  Subset of over or under represented kinases are conserved across 
mouse and human cells.  The kinome from Stable CCM2 shRNA knock down 
Huvecs and MEECs were compared with many kinases showing conserved 
changes.  Red boxes highlight the kinases changed in opposite direction after 
pharmacological inhibition of ROCK with 10 µM Y27632 for 48 hours.   
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Figure 3.5: CCM1 protein loss affects the kinome. Stable shRNA knock down 
was achieved in Huvecs and the kinome was profiled.  Error bars represent the 
average of at least two experiments where a kinase was quantified; three 
independent experiments were conducted.    
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Figure 3.6: CCM3 protein loss affects the kinome. Stable shRNA knock down 
was achieved in Huvecs and the kinome was profiled.  Error bars represent the 
average of at least two experiments where a kinase was quantified; three 
independent experiments were conducted.   
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Figure 3.7: A subset of over or under represented kinases are conserved 
across CCM1 and CCM2 deficient Huvecs.  Error bars represent the average of at 
least two experiments where a kinase was quantified; three independent 
experiments were conducted   
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Figure 3.8: A subset of over or under represented kinases are conserved 
across CCM2 and CCM3 deficient Huvecs. Error bars represent the average of at 
least two experiments where a kinase was quantified; three independent 
experiments were conducted  
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Figure 3.9: A subset of over or under represented kinases are conserved 
across CCM1 and CCM3 deficient Huvecs. Error bars represent the average of at 
least two experiments where a kinase was quantified; three independent 
experiments were conducted   
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Figure 3.10: A subset of over or under represented kinases are conserved 
across CCM1, CCM2, and CCM3 deficient Huvecs. Error bars represent the 
average of at least two experiments where a kinase was quantified; three 
independent experiments were conducted  
	   Down	  	   Up	   Total	  
CCM1/CCM2	   48	   37	   85	  
CCM2/CCM3	   51	   40	   91	  
CCM1/CCM3	   58	   39	   97	  
CCM1/2/3	   36	   26	   62	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Figure 3.11: Kinases important for endothelial function are deregulated in 
CCM1, -2, and -3 deficient Huvecs.  TGF-βR1, TGF-βR2, and Tie2 are strongly 
overrepresented, whereas BMX is strongly underrepresented. LIMK signaling also is 
overrepresented with CCM1 and CCM2 deficient cells having increased LIMK1 and 
CCM3 deficient ECs having increased LIMK2.  ROCK1 and ROCK2 are differentially 
regulated in CCM2 and CCM3 deficient ECs, and CCM1 unexpectedly has 
decreased ROCK1/2 levels.  Error bars represent the average of at least two 
experiments where a kinase was quantified; three independent experiments were 
conducted   
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Figure 3.12:  pLIMK1 is increased in stable CCM1, -2, or -3 knock down 
MEECs.  A).  Loss of CCM proteins increases pLIMK1/2 but not total LIMK1, 
suggesting that LIMK activation is effected.  shRNAs against LIMK1 by in large 
decrease this signal, suggesting that most of the signal is from LIMK1 and not 
LIMK2.  B). The activation of LIMK1 is downstream of ROCK as inhibition of ROCK 
activity by Fasudil decreases pLIMK1.  (*P <.05 from independent experiments) 
(*Courtesy of Dr. Christopher Dibble).  
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Figure 3.13:  pCofilin levels are increased by LIMK1 following CCM protein 
loss A).  Loss of CCM proteins increases pCofilin levels, and double stable 
knockdowns for CCM1, -2, or -3 with LIMK1 rescue these elevated pCofilin levels.  
B).  Two independent shRNAs for LIMK1 decrease pCofilin in CCM2 knock down 
cells.  C).  pMLC2 is elevated in CCM2 knock down cells but LIMK knock down is 
unable to decrease these elevated levels suggesting that LIMK1 is only effecting the 
pCofilin arm of the RhoA/ROCK pathway. (*P <.05 from independent experiments) 
(*Courtesy of Dr. Christopher Dibble).    
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Figure 3.14:  Knock down of LIMK1 is sufficient to rescue CCM phenotypes in 
vitro A).  Loss of CCM proteins decreases endothelial tube forming ability that is 
rescuable with ROCK inhibition (10 µM Y27632) or stable knock down of LIMK1. B). 
Time course analysis of endothelial tube formation shows that CCM2 deficient ECs 
are unable to make cell contacts and elongate into tube structures, where as cells 
treated with ROCK inhibitor or LIMK1 knock down are able to start forming cell-cell 
contacts and elongate similar to control cells after 4-6 hours.  Images were taken at 
10X magnification (*P <.05 from independent experiments) (*Courtesy of Dr. 
Christopher Dibble).    
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Figure 3.15:  Elevated pCofilin staining is observed in surgically resected 
human CCM1, -2, and -3 lesions A). pCofilin antibody was validated by showing to 
elevated pCofilin levels in paraffin embedded MEECs with stable CCM1, -2, or -3 
knock down.  B).  Advanced QUantitative Analysis (AQUA) was used to quantitate 
pCofilin levels by immunoflourescence.  C).  Human lesions with sequence verified 
CCM1, -2, or -3 mutations but not adjacent normal brain endothelial tissue display 
elevated pCofilin staining in the endothelium by immunohistochemistry.  D).  pCofilin 
is elevated by immunoflourescence of human CCM lesions and overlays perfectly 
with a CD31 (endothelial specific mask), indicating that pCofilin is elevated only in 
the endothelium (right panel).  E).  AQUA of immunoflourescence shows between a 
4 and 10 fold increase in pCofilin signal when compared to normal brain tissue.  F).  
Table listing the CCM1, -2, and -3 patient mutations from the stained lesions. (*P 
<.05 from independent experiments). 
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Figure 3.16: Tie2 and BMX are increased both at protein and mRNA levels in 
Huvecs after CCM1, -2, or -3 loss.  A). Tie2 and RhoA protein expression is 
increased after CCM1, -2, or 3 knock down in Huvecs.  B). Densitometry 
quantification of three separate experiments on Tie2 levels normalized to Erk2.  C). 
BMX protein is down regulated and RhoA protein levels are increased after loss of 
CCM2. Proteasome inhibition by MG132 is insufficient to rescue BMX. D).  Tie2 
message levels are increased and BMX message levels are decreased by qRT-
PCR. 
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Figure 3.17: Tie2 and BMX message levels are not significantly affected by 
ROCK inhibition. Huvec cells with stable knock down of CCM1 or CCM3 were 
treated with 10 µM ROCK for 48 hours.  No significant changes in message levels of 
Tie2 or BMX were detected (N=2 separate experiments). 	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Figure 3.18: qRT-PCR analysis of knock down lines used for chapter III.  A).  
Stable double knock down of CCM1 and Limk1 in MEECs.  B).  Stable double knock 
down of CCM2 and Limk1 in MEECs.  C).  Stable knock down of CCM3 and Limk1 
in MEECs.  D).  Stable knock down of CCM1, -2, and -3 in Huvecs 
 
 
 
 
 
IV.  Ubiquitin ligase mediated degradation of RhoA as a molecular mechanism 
deregulated in CCM protein deficient ECs. 
 
Introduction 
Recent studies have increased our understanding of how CCM protein loss 
contributes to endothelial cell dysfunction and lesion generation.  It has become 
apparent that elevated RhoA/ROCK signaling leads to CCM pathogenesis.  
Currently, it is unknown how RhoA becomes over activated in CCM.  There have 
been no published studies examining canonical GEF or GAP regulation of RhoA, 
and we have led unsuccessful attempts in uncovering known RhoA GEF or GAPs 
that function downstream of the CCM proteins.  However, we have consistently 
observed increases in total RhoA protein without subsequent increases in RhoA 
message levels following knock down of CCM proteins [4, 5].  This information 
suggests that the degradation of RhoA is being affected by CCM protein loss.   
There have been numerous findings that suggest degradation is an important 
mechanism behind the regulation of small GTPase function [198].  The degradation 
of RhoA was observed after stimulation of CNF1 led to increased activation of RhoA 
[199, 200]. Currently, only the Smurf1 and cullin 3 E3 ubiquitin ligases have been 
found to degrade RhoA with Smurf1 selectively degrading active RhoA and cullin 3 
targeting total RhoA [76, 116].  We have previously established that Smurf1 binds to 
CCM2 in a PTB dependent manner, which is in line with degradation as a potential 
molecular mechanism regulating RhoA levels.  This interaction in Cos7 cells results 
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recruits Smurf1 to the cell membrane resulting in a cell spreading effect.  CCM2 
overexpression along with Smurf1 led to a CCM2 dose dependent decrease in RhoA 
levels.  CCM2 is neither a substrate of Smurf1 nor does it affect Smurf1 catalytic 
function [5].  Thus, deregulated Smurf1 is an attractive candidate driver of the 
increased RhoA signaling observed in CCM. In addition to RhoA, Rap1 is also 
degraded by a structurally similar E3 ubiquitin ligase Smurf2. This degradation 
results in selective degradation of Rap1 in retracting neurites after correct 
membrane localization by mPar3 [111, 112].  Based on the ability of CCM2 to bind 
Smurf1 and regulate its localization, we sought to investigate the ability of the CCM 
proteins to bind the other E3 ubiquitin ligases Smurf2 and cullin 3 and how that 
affects EC phenotypes.   
In this study, we demonstrate that Smurf1, Smurf2, and cullin 3 phenocopy 
the loss of CCM proteins through the differential regulation of RhoA and Rap1.  
CCM2 but not CCM1 or CCM3 bind to Smurf1, and this interaction occurs 
endogenously.   We further show that CCM2 is able to interact with Smurf2, which 
provides a potential link for Smurf2 in regulating Rap1 levels in CCM.  Lastly, we 
demonstrate that RhoA protein levels are elevated following CCM protein loss 
through decreased ubiquitination of the GTP bound form of RhoA and a steady 
accumulation of RhoA protein.  
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Results 
CCM2 but not CCM1 or CCM3 bind to Smurf1, promoting the degradation of GTP 
bound RhoA 
Smurf1 has been shown to selectively degrade GTP bound RhoA, and the 
CCM disease state occurs from over active RhoA.  Therefore, we focused our 
attention to whether Smurf1 was affecting the poly ubiquitin levels of GTP bound 
RhoA.  We first began by interrogating the CCM ternary complex to determine 
whether Smurf1 binds to CCM1 or CCM3. Using transfected proteins, we only 
detected co-immunoprecipitated Smurf1 with CCM2 and not CCM1 or CCM3, which 
was abrogated with a single point mutation in the PTB domain of CCM2 (Fig 4.0 A 
and B).  We also detected this interaction between endogenous CCM2 and Smurf1, 
indicating this interaction is physiological at a cellular level (Fig 4.0 C). This result 
suggests that CCM2 interacts with Smurf1, where as CCM1 and CCM3 may have an 
indirect role in regulating Smurf1 activity or are required for further localization of the 
complex through their respective independent interactions with CCM2.   
We sought to detect the levels of endogenously ubiquitinated GTP RhoA by 
utilizing the Rho binding domain from Rhotekin to pull down GTP bound RhoA 
followed by ubiquitin immunoblotting [201].  We treated all cells with the proteasome 
inhibitor MG132 for 6 hours to stabilize poly ubiquitinated proteins. To determine the 
specificity of this assay for GTP bound RhoA, we knocked down total RhoA protein 
by shRNA and blotted for ubiquitin.  We detected a complete loss in both total RhoA 
and GTP bound RhoA with a nearly complete loss in ubiquitin signal when quantified 
and compared to Plko.1 control cells from independent experiments (Fig 4.1A and B).  
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This result indicates that we are preferentially detecting ubiquitinated GTP bound 
RhoA with little to no RhoB or RhoC background.  This finding is likely because the 
other Rho members are degraded through the lysosomal protein degradation 
pathway and do not utilize the ubiquitin proteasome system (UPS) [202].   
Therefore, we sought to determine whether the loss of CCM proteins also 
affects ubiquitinated GTP bound RhoA.  We were able to generate stable knock 
down CCM1, -2, or -3 in ECs and observed large increase in both activated GTP 
bound RhoA and total RhoA protein (Fig 4.1A and 4.8 A-E).  These increases were 
followed by a significant decrease in ubiquitinated GTP bound RhoA, and after 
quantification of multiple experiments, ubiquitinated GTP bound RhoA was 
decreased to baseline levels (Fig 4.1A and B).  Similarly, the loss of Smurf1 
increased total and active GTP bound RhoA with a concomitant decrease in 
ubiquitinated GTP bound RhoA (Fig 4.1 A and B).  This decrease in ubiquitinated 
GTP bound RhoA signal is detected even though there is far more GTP bound RhoA 
in the pull down from CCM1, -2, 3, or Smurf1 deficient cells.  These data indicate 
that the CCM protein complex first defined in Hilder et al. functions, in part, to 
regulate the ubiquitination status of GTP bound RhoA with CCM2 directly 
coordinating Smurf1.  Other groups have observed increases in activated RhoA 
without increases in total RhoA.  We hypothesize that the loss of Smurf1 leads to the 
steady accumulation of GTP bound RhoA, which over time may contribute to 
increases in total RhoA protein [76, 93].  This observation may not be realized with 
the use of transient siRNA approaches that have been used previously.  To 
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definitively prove this hypothesis, additional studies into the spatial temporal 
degradation of activated RhoA versus total RhoA are required. 
 
Forskolin stimulates longer term RhoA degradation and Mst3/4 kinases 
phosphorylate Smurf1 
The mechanism behind how the CCM protein complex regulates total and 
active RhoA levels is unknown.  Phosphorylation of RhoA upon Serine 188 protects 
RhoA from UPS mediated degradation in vascular smooth muscle cells [203].  This 
phosphorylation event functionally promotes the association of RhoA with RhoGDI 
and extracts RhoA from the membrane [204].  Therefore, we wanted to interrogate 
whether this system is conserved in ECs.  Forskolin is an agonist of adenylyl cyclase 
and functions to produce the cyclic adenosine monophosphate (cAMP) second 
messenger, which is critical to the activation of protein kinase A (PKA).  Therefore, 
we sought to determine if RhoA levels are sensitive to elevated cAMP/PKA signaling 
in ECs.  We observed that active RhoA levels decrease, and there is a spike in total 
RhoA levels within several hours following the administration of Forskolin.  These 
levels remain high after 26 hours of treatment (Fig 4.2 A and B).  The total RhoA 
levels are decreased below WT levels after 36 hours, which is in contrast to the 
more rapid turnover of RhoA following treatment with cycloheximide (CHX) (Fig 4.2 
C and D).  These data are consistent with previous studies demonstrating that the 
half-life of a Ser188 phospho-mimetic RhoA is increased after 6 hour treatment [203].  
However, the decrease in RhoA with longer treatment of Forskolin is unknown and 
may indicate a more dynamic regulation of RhoA turn over.  Proteasome inhibition 
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with MG132 was able to rescue the total RhoA levels after prolonged forskolin 
treatment, suggesting that RhoA is being degraded through the UPS, potentially 
through Smurf1 (Fig 4.2 C and D).  We further have observed decreased PKA-β 
(KAPCB) subunit activity following loss of CCM1 and CCM3 by MIB/MS profiling (Fig 
3.9).  Therefore, additional studies are needed to determine if the CCM protein 
complex is regulating PKA mediated phosphorylation and subsequent degradation 
kinetics of RhoA.  Overall, these data indicate that a component of adenylyl 
cyclase/PKA signaling functions to regulate RhoA stability in ECs.   
CCM3 interacts with several of the sterile kinases, including Mst3 and Mst4, 
which phosphorylated the ERM proteins among other proteins directly on 
serine/threonine residues, which leads to decreased RhoA activity [205].  This 
regulation of phosphorylation activity by CCM3 could provide a link for CCM3 and 
Smurf1 regulation.  Smurf1 substrate switching specificity from the SMADs to RhoA 
is determined by increased phosphorylation of Smurf1 at T306 downstream of PKA 
[108].  Therefore, we wanted to determine if either Mst3 or Mst4 phosphorylates 
Smurf1.  Using an in vitro kinase assay, we detected the phosphorylation of GST 
purified Smurf1 at approximately 20% of Mst3 and 4 autophosphorylation (Fig 4.2 E).  
Mst3 and 4 autophosphorylation is required for their proper activation and Mst3 
autophosphorylation is decreased after Smurf1 substrate addition (Fig 4.2 E).  While 
this hypothesis is speculative, it is possible that CCM3 binding to Mst3 and 4 
contributes to the CCM ternary complex regulation of RhoA degradation through 
PKA or STE family kinases, which may mediate Smurf1 substrate switching.  
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In vitro loss of Smurf1 and cullin E3 ligases increase F-actin stress fibers and 
decrease endothelial cell tube formation ability 
We next determined the functional consequences of Smurf1 loss in stably 
transduced ECs and whether that loss phenocopies CCM protein loss.  Stable 
shRNA mediated knock down of Smurf1 by two different shRNAs led to a significant 
increases in actin stress fibers (Fig 4.3A and C).  This result is consistent with the 
loss of CCM1, -2, or -3 and increases in active RhoA following Smurf1 knock down.  
These actin stress fibers were decreased following treatment with the ROCK 
inhibitor Y27632, indicating that Smurf1 is affecting RhoA-ROCK signaling (Fig 4.3A 
and C). This increase in cellular F-actin also decreased tube formation ability, which 
was partially rescued by ROCK inhibition (Fig 4.3 B and D).  Together these data 
further suggest that Smurf1 functions alongside CCM proteins to directly regulate 
activated RhoA.  
The cullin E3 ring ligases are purported to affect the ubiquitination status of 
total RhoA protein.  Cullins function similarly to the Smurf proteins through an E1, E2, 
E3 enzyme ubiquitin transfer cascade which increases substrate specificity [115].  
Importantly, the loss of the cullin 3 E3 ligase has been shown to increase RhoA 
protein levels and stress fiber formation [116, 117].  This effect results from the 
decreased ubiquitination of total RhoA protein, which leads to a steady accumulation 
of activated RhoA protein.  This process is in reverse for Smurf1, which degrades 
activated RhoA protein followed by a concomitant increase in total RhoA protein [93, 
109].  We, thus sought to understand if the cullin E3 ligases are directly changing 
total RhoA protein levels.  To address this question, we used a commercially 
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available cullin ligase inhibitor MLN 4924.  This inhibitor blocks the neddylation 
activating enzyme (NAE) [206].  Total protein degradation inhibition by MG132 or 
bortezomib is over 50% where as MLN 4924 only blocks 9% of total protein turn over 
[207].  For cullin E3 ligases to function properly, the neddylation factor NEDD8 is 
transferred sequentially to the E1, E2, and E3 enzymes in an ATP dependent 
fashion.  This final NEDD8 conjugation to the cullin family of ligases is required for 
recruitment of E2 conjugating enzymes, release of the negative regulator Cand1, 
and overall activation of the ubiquitinating complex [207].  Tube-like structures were 
significantly ablated when cells were plated in a Matrigel tube formation assay after 
treatment with MLN 4924 (Fig 4.4A).  Stress fibers and total RhoA protein levels 
were also increased, which is consistent with the role of cullin ligases in regulating 
RhoA (Fig 4.4 B, C, and D).  Importantly, stress fibers and tube forming ability were 
significantly rescued when ROCK was inhibited by Y27632 (Fig 4.4 A, C, and D).  
This result indicates that blocking neddylation by MLN 4924 increases total RhoA 
protein.   
The magnitude of RhoA protein increase and relative short timing of this 
increase indicates that total RhoA protein degradation is being affected.  This result 
is expected because the estimated total amount of GTP bound RhoA in cell culture 
is quite low at only 5% [208].  To examine this process, we immunopreciptated total 
RhoA proteins and then immunoblotted for ubiquitin in wild type cells and in cells 
treated with MLN 4924 for 24 hours.  MLN 4924 treatment significantly increased 
RhoA total levels while decreasing ubiquitinated RhoA (Fig 4.5A).  This decrease in 
ubiquitinated total RhoA was more than the decrease observed in Smurf1 knock 
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down cells (Fig 4.5B).  Thus, these data suggest that Smurf1 is ubiquitinating the 
activated form of RhoA more selectively, and cullin ligases are ubiquitinating the 
total form of RhoA in ECs.  We next wanted to ascertain if the cullin 3 ligase was 
influencing RhoA signaling as has been previously reported.  After stable knock 
down of cullin3 in ECs we noted an increase in F-actin stress fibers and concomitant 
loss in tube forming ability, which were rescued by ROCK inhibition with Y-27632. 
(Fig. 4.6A and B).  A large increase in pMLC2 levels were observed after Smurf1 
knock down and a lesser extent in cullin 3 knock down cells, suggesting that the 
levels of activated RhoA are higher in Smurf1 deficient cells (Fig 4.6 C).  This finding 
is consistent with previous studies and our hypothesis of Smurf1 degrading activated 
RhoA and the cullin ligases degrading total RhoA. 
 
Smurf2 binds CCM2 and is required for proper endothelial tube formation through 
regulation of Rap1. 
Rap1 regulation is central to endothelial junction stability and is regulated by 
CCM1 [62, 95].  Smurf2 also degrades Rap1A in neurons and based upon its 
similarity to Smurf1, we investigated the effects of Smurf2 loss in ECs.  Accordingly, 
after stable shRNA knock down of Smurf2 we noted a large decrease in tube 
formation ability (Fig 4.7 A and B).  In contrast to Smurf1 knock down ECs, this 
phenotype was not rescued by ROCK inhibition, suggesting that Smurf2 degrades 
Rap1 with no effect on RhoA (Fig 4.7 A and B).  Accordingly, we noted that Rap1 but 
not RhoA levels were increased by western blotting after Smurf2 knock down (Fig 
4.7 C).  This finding further suggests that the selectivity of Smurf1 and Smurf2 
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between RhoA and Rap1, which has been noted in other cell models, is conserved 
in ECs.  Smurf2 is highly similar to Smurf1 and contains a HECT domain.  CCM2 
and Smurf1 interact selectively through this HECT domain [5].  We found that 
Smurf2 was able to co-immunoprecipitate CCM2 using overexpressed proteins (Fig 
4.7 D).  Stable knock down ECs for CCM-1, -2, and -3 increased Rap1 protein levels, 
which further links Rap1, Smurf2, and the CCM proteins in the same pathway (Fig 
4.7 E).  These data indicate a novel interaction between CCM2 and Smurf2, which 
may function to regulate the overall stability of Rap1 protein.  Furthermore, 
deregulated Smurf2 activity, likely due to the loss of CCM2, aberrantly affects tube 
formation ability.    
 
Discussion 
In this study, we have demonstrated that three different E3 ubiquitin ligases 
function to regulate RhoA and Rap1 in ECs.  The phenotypes associated with loss of 
either Smurf1, Smurf2, or the cullin family of ligases are highly related.  Smurf1 
function is the most elucidated and binds CCM2 directly and not CCM1 or CCM3; 
CCM2 recruits it to membrane at areas of active cellular protrusions.  CCM1 and 
CCM3 do not bind directly to Smurf1, yet they yield virtually the same phenotypes 
and demonstrate deregulated active RhoA ubiquitination.  Thus, we posit that the 
integrated functions of CCM1, -2, -3 as a ternary complex are required for the proper 
degradation of RhoA in ECs.  CCM2 functions to recruit Smurf1 and CCM1 to the 
membrane where CCM1 has been shown to selectively bind to the VEcadherin 
junction protein [62, 209].  CCM1 is required for the proper localization of PKCζ at 
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the membrane, which is required for Smurf1 ubiquitination of RhoA at sites of active 
cellular protrusions [76, 209].  These functions of CCM1 may shed light into how the 
loss of CCM1 is identical to the loss of CCM2.  Furthermore, CCM3 interacts with 
several of the sterile kinases, including Mst3 and Mst4, which phosphorylated ERM 
proteins directly [205].  This regulation of phosphorylation activity by CCM3 could 
provide a link for CCM3 and Smurf1 regulation.  We observe that increased adenylyl 
cyclase stimulation results in immediate GTP bound RhoA turn over followed by total 
RhoA.  Furthermore, the CCM3 interactors Mst3 and Mst4 phosphorylate Smurf1 in 
vitro.  More study is needed to determine if adenylyl cyclase regulates RhoA 
phosphorylation and turn over and how relevant our in vitro phosphorylation data is 
in Smurf1 substrate selection in ECs. While highly speculative at this point, the 
ability for CCM1 to regulate PKCζ membrane localization and a putative function for 
CCM3 protein mediated Smurf1 phosphorylation substrate switching could explain 
how CCM1 and CCM3 function as a complex with CCM2 in regulating Smurf1 
function. 
The cullin E3 ligases are instrumental regulators of RhoA degradation.  We 
show for the first time that this system is conserved in endothelial cells with 
phenotypes that mimic the loss of any of the CCM proteins.  We have further shown 
the cullin ligases preferentially regulate total RhoA levels where as Smurf1 degrades 
the active form of RhoA.  Furthermore, this effect seems to be mediated through the 
cullin 3 ligase as has been previously established in other cell systems.  We have 
been unsuccessful in demonstrating a binding interaction between the CCM proteins 
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and cullin 3 (data not shown).  Therefore, these phenotypes need a further link to the 
CCM proteins. 
Among many targets, the Smurf2 E3 ligase degrades Rap1 [111].  Previous 
studies have demonstrated the importance of proper Rap1 function in maintaining 
junction stability with CCM1 central to its regulation in ECs [62, 95].  We show that 
loss of Smurf2 decreases the tube forming ability of ECs, which phenocopies loss of 
the CCM1, -2, or -3.  This effect is likely not due to RhoA/ROCK signaling as CCM1, 
-2, and -3 loss increased Rap1 protein but not RhoA, and no rescue was achieved 
with ROCK inhibition.  We cannot exclude the possibility that the tube formation 
defects are due to the deregulation of other Smurf2 targets without a proper rescue 
experiment. In addition, the effects on Rap1 turnover need to be further examined to 
determine whether active or total Rap1 is being affected in a manner similar to RhoA 
regulation.  We establish a novel interaction between CCM2 and Smurf2, suggesting 
that the CCM protein complex may be involved in regulating Smurf2 function.  The 
interaction mapping needs to be determined if this interaction occurs through a PTB 
and HECT domain dependent fashion.  Rap1 and RhoA have opposing functions on 
EC junctions; therefore, it is interesting that both are increased following the loss of 
CCM proteins.  This dual increase could differ depending on the activation status of 
the endothelium in states of active angiogenesis vs. endothelial quiescence.  Thus, 
further spatial/temporal study is needed to elucidate when the CCM proteins 
degrade RhoA compared to Rap1 during angiogenesis and if this correlates to when 
the CCM complex is bound to either Smurf1 or Smurf2.   
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As the small GTPase field has progressed over the past two decades, the 
role of small GTPase degradation has become more and more relevant to many 
cellular processes.  Our data suggest that selective RhoA degradation coordinated 
by the CCM proteins is an important portion of RhoA regulation in ECs.  We have 
provided novel data, which suggests that the cullin E3 ubiquitin ligases and Smurf2 
function to regulate total RhoA and Rap1 stability down stream of the CCM proteins, 
respectively.  Thus, deregulated degradation of small GTPase proteins is at least 
one potential molecular mechanism driving CCM phenotypes.
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Figure 4.0: Smurf1 binds to CCM2 and not CCM1 or CCM3.  A). HEK293T cells 
were transfected for 12 hours with Flag Smurf1 and GFP tagged CCM1, -2, or -3.  
Flag immunoprecipitants were then blotted with a GFP antibody, demonstrating that 
Smurf1 interacts with CCM2 and not CCM1 or CCM3 (IP top panel; Input lower 
panel).  B). HEK293T cells were transfected with Flag Smurf1 or GFP tagged CCM2 
WT or CCM2F217A. Flag immunoprecipitants were blotted with a GFP antibody, 
demonstrating CCM2 but not the F217A PTB domain mutant binds to Smurf1 (IP top 
panel; Input lower panel).  C).  Endogenous Smurf1 was immunoprecipitated from 
wild type huvec lysates or shCCM2 lysates, demonstrating that CCM2 interacts with 
Smurf1 endogenously. 
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Figure 4.1: Ubiquitinated GTP bound RhoA is decreased after CCM protein 
loss.  A). Stable shRNA knock down CCM1, -2, -3, Smurf1, and RhoA in MEECs 
were generated and treated with or without 20 µM MG132 for four hours as 
indicated.  The RBD from Rhotekin was used to pull down GTP bound RhoA and a 
specific ubiquitin antibody was then used to probe for ubiquitinated RhoA. B). 
Quantification of ubiquitinated GTP RhoA.  All knock down lines demonstrated a 
large decrease in ubiquitinated GTP bound RhoA.  Quantification was normalized to 
GTP bound RhoA and Erk2; error bars represent at least 3 independent biological 
experiments. 
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Figure 4.2:  Adenylyl cyclase activation by Forskolin promotes RhoA 
degradation A).  Forskolin treatment of Huvecs decreases RhoA GTP levels after 
two hours and increases total RhoA levels.  B).  Total RhoA protein levels 
progressively decrease following Forskolin treatment but remain higher than 
baseline after 26 hours.  C).  Total RhoA protein levels decrease below baseline 
levels after 36 hours of Forskolin treatment, and this decrease is rescued by the 
proteasome inhibitor MG132.  D).  The half life of RhoA is approximately 6-8 hours 
after protein translation inhibition by CHX addition, which is rescued with MG132 
proteasome inhibition.  E).  The Mst3 and Mst4 kinases are autophosphorylated and 
phosphorylated Smurf1, autoradiographic densitometry quantification is shown in the 
right panel.  Forskolin was added at 10 µM and MG132 was added at 20 µM for the 
indicated times.    
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Figure 4.3:  Loss of Smurf1 increases stress fiber formation and decreases 
tube forming ability of Huvecs. A). Huvecs were grown to confluency with knock 
down of either Smurf1 or CCM2 and were treated with or without ROCK inhibitor Y-
27632 (10 µM).  Actin was stained with phalloidin, demonstrating that stress fibers 
were increased with two independent shRNAs for Smurf1 and CCM2, which was 
rescued with ROCK inhibition.  B).  Smurf1 and CCM2 knock down huvecs were 
seeded in a Matrigel tube formation assay.  WT cells demonstrated robust tube 
forming ability, where as loss of Smurf1 or CCM2 strongly disrupted tube formation, 
which was rescuable with ROCK inhibition.  C and D).  Quantifications of stress 
fibers and tube formation assays; error bars represent at least two independent 
experiments. 
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Figure 4.4:  Cullin inhibitor MLN 4924 increases stress fibers, decreases tube 
formation, and increases RhoA protein.  A).  Tube formation was strongly 
inhibited in a ROCK dependent fashion after Huvecs were treated with 10 µM MLN 
4924 overnight.  B).  RhoA protein levels, assessed by immunoblotting, were 
substantially increased in huvecs after treatment with 10 µM MLN 4924 overnight.  C 
and D).  ROCK dependent actin stress fibers were increased in Huvecs treated with 
10 µM MLN 4924 overnight. 
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Figure 4.5:  MLN 4924 treatment decreases the ubiquitination of total RhoA 
protein.  A).  The total RhoA ubiquitin ladder is decreased in huvec cells treated 
with 10 µM MLN 4924 for 24 hours . B).  Smurf1 knock down huvecs have a less 
pronounced decrease in total RhoA ubiquitinated protein levels when compared to 
MLN 4924 treated huvecs.  Cells were treated with MG132 for 4 hours at 20 µM to 
stabilize poly ubiquitinated proteins. 
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Figure 4.6:  Stable cullin 3 knock down increases stress fibers and decreases 
tube forming ability.  A).  Tube formation was strongly inhibited in a ROCK 
dependent fashion after cullin 3 was stably knocked down in Huvecs.  B).  Actin 
stress fibers were increased in a ROCK dependent fashion after cullin 3 was stably 
knocked down in Huvecs.  C).  pMLC2 levels were increased after cullin 3 knock 
down but to a lesser extend than in Smurf1 stable knock down Huvecs.  
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Figure 4.7:  Smurf2 regulates the turn over of Rap1.  A).  Tube formation was 
strongly inhibited in Huvecs following stable knock down of Smurf2.  B).  
Quantification of tube area and length demonstrates that ROCK inhibition does not 
rescue Smurf2 mediated tube formation defects.  C).  Two independent Smurf2 
shRNAs increase Rap1 protein levels but not RhoA in Huvecs.  D).  Flag Smurf2 is 
able to co-immunoprecipitate CCM2.  E).  Loss of either CCM1, -2, or -3 in Huvecs 
increases Rap1 protein levels.   
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Figure 4.8: qRT-PCR and western blotting analysis of knock down lines used 
for chapter IV.  A).  Stable knock down of CCM1, -2, and -3 in Huvecs. B).  Stable 
knock down of CCM1, -2, and -3 in MEECs. C).  Stable knock down of Smurf1, 
Smurf2, and Cullin3 in Huvecs.  D).  Stable knock down of Smurf1 in MEECs.  E).  
Knock of RhoA in MEECs   
 
     
 
  
 
 
 
 
 
V.  Induced pluripotent stem cells as a new patient specific model for CCM. 
 
Introduction 
Currently, the only models available for the study of CCM are various mouse 
and human endothelial cell lines and mouse genetic models.  These model systems 
have led to the current understanding of signaling mechanisms that underlie CCM.  
Healthy cell lines are robust in vitro tools for investigation into the signaling 
mechanisms underlying CCM, and siRNA technology allows for the knock down of 
each CCM gene followed by observations in cell behavior.  Yet these models have 
not always been consistent.  For example, several studies have shown that loss of 
CCM3 leads to increased RhoA signaling and actin stress fiber formation; whereas 
another study challenged these findings showing that knock down of CCM3 in 
human cells had little to no effect on stress fiber formation or pMLC2 levels [4, 6, 87].  
Furthermore, several studies have been inconclusive into the effects of CCM1, -2, 
and -3 in aspects of cellular proliferation and endothelial sprouting in fibrin bead 
assays [4, 8, 45, 210].   
These differences could be a side effect of the type of siRNA approach used 
to knock down ccm gene expression.  Transient siRNA efficiently knocks down gene 
expression in a subset of cells, which are transfected but wanes there after.  In 
contrast, stable shRNA integrates into the host cell genome in most of the plated 
cells and can knock down genes permanently.  Most studies have assessed knock 
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down through qRT-PCR, which doesn’t assess whether residual CCM protein is 
available after CCM mRNA loss.  Thus, the underlying signaling differences may be 
more sensitive to knock down efficiency and residual protein than broad endothelial 
cell phenotypic defects.  Furthermore, every siRNA or shRNA has potential off target 
effects to proteins with similar seed sequences.  Therefore, some of the phenotypic 
differences could be attributable to unrelated proteins being targeted by the siRNA.  
In addition to the problems with siRNA technology, cell culture lines have intrinsic 
differences. These arise from the many different endothelial cell lines that have been 
used in CCM studies.  The most broadly used in the context of CCM studies are 
Huvecs.  These cells have general shared characteristics with all other endothelial 
cells; however, they are derived from a tissue, which does not form CCM lesions and 
may not necessarily recapitulate CCM signaling.  More physiologically relevant 
endothelial cell types are human brain microvascular endothelial cells (Hbmvecs).  
These cells are from brain tissue where CCM lesions form and likely represent a 
more relevant cell type to study CCM signaling.  In lieu of these suppositions, a 
recent study found that endothelial cells isolated from CCM patient lesions have 
enhanced migration, where as CCM knock down Huvecs or Hbmvecs do not [211].  
Cell culture practice and passage number can exasperate these differences.  Thus, 
a complex understanding of CCM requires a more rigorous approach that entails the 
use of diseased endothelial cells from patients.   
Mouse models have become a powerful tool for understanding lesion 
formation in CCM.  These models utilize genetic knock out approaches and are not 
hampered by partial knock down or siRNA off target effects. Developmentally, CCM 
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protein knock out in the mouse is embryonic lethal due to improper embryonic heart 
development and vascular patterning [40, 41]. However, unlike human familial 
carriers, CCM protein heterozygous mouse models never form lesions [8].  Adult 
mouse lesions could only by generated by breeding CCM heterozygous mice into a 
p53 null or MSH2 null background, which have increased genomic instability.  These 
mice were powerful tools that potentially proved the loss of heterozygosity 
hypothesis, allowed for the study of lesion generation, and gave an in vivo 
evaluation of Rho kinase inhibitor treatments for CCM [8].  However, these second 
generation models are not representative of CCM patient genomic backgrounds as 
CCM patients do not have increased rates of tumor formation due to the loss of p53 
or DNA repair machinery.  Nonetheless, these observations of genomic instability 
and CCM protein loss have raised important questions as to the heterogeneity of 
CCM lesion formation in common pedigrees and whether patient genomic 
background or stability within ECs play an important role in CCM lesions.  
Therefore, studying diseased cells from patients is paramount because it is 
possible to determine if the phenotypes established in heterologous human and 
mouse cell culture systems are valid.  This research strategy will allow for a more 
confident approach in testing therapeutics and designing CCM clinical trials. 
Symptomatic CCM lesions typically occur in the brain in areas that are difficult to 
obtain good biopsies for the extraction of cell culture.  To date only one study has 
been undertaken to isolate CCM lesion endothelial cells [174].  The phenotypic data 
generated from this study was very limited because of low cell numbers, slow 
cellular growth rates, and purity.  The iPS field has taken disease modeling to task 
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with substantial progress in numerous rare and hard to study diseases. iPS cells 
generated from already sequenced CCM patients would allow for the generation of a 
library of diseased cells encompassing the genomic background of human patients. 
iPS cells are immortal and have been cultured continuously for a year [212].  Thus, it 
is thought that they are like hESCs and are an immortal and karyotypically normal 
cell type due to the expression of telomerase.  This characteristic of iPS cells will 
preserve valuable patient cells for indefinite periods of time and study.  
The science behind generating iPS cells has progressed rapidly and is still 
burgeoning.  First generation iPS cells comprising approximately 80% of all 
published iPS lines were generated by retroviral or lentiviral ectopic expression of 
reprogramming cocktails including Oct4, Sox2, Klf4 (or Nanog) and a proliferative 
driver such as cMyc (or SV40) [146].  Each of these genes have been associated 
with teratocarcinoma growth, cell transformation and genome instability.  Second-
generation methodologies for generating iPS cells have ameliorated some of the 
problems with ectopic retroviral integration and have increased the fidelity and 
genomic stability of the resulting iPS cells.  These methods utilize non-integrating 
approaches, such as RNA transfection, episomal vector electroporation, and sendai 
virus [146].  These cells are more similar to hESC cells with the only drawback being 
a lower efficiency of generation. These approaches only transiently express 
reprogramming factors and the cells are at a lower risk for further transformation with 
time in culture.  Therefore, the generation of CCM patient iPS cells will benefit from 
the newer methods for iPS cell generation. 
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iPS cells can be readily differentiated into all major cell lineages including 
endothelial cells, which are thought to be the cell type most affected by genetic loss 
of the CCM proteins.  iPS cells spontaneously differentiate upon the removal of 
basic Fibroblast growth factor (bFGF) from the cell culture media into cells 
representing all three germ layers [213].  Typically, differentiation is initiated by 
generating embryoid bodies (EBs).  EBs are non-adherent spherical structures, 
which stochastically differentiate into cells of all three developmental germ layers. 
Appropriate inducing cytokines can be added to direct cells within these EBs to form 
specific cell types (Fig 1.2).  Endothelial vessel like structures cells were shown to 
differentiate from hESCs in EBs after 13-15 days [214].  These ECs could form tube-
like structures both in EBs imaged by confocal microscopy, on Matrigel, and 
contribute to the vasculature when tissue scaffolds were implanted into mice.  They 
also expressed selective endothelial specific genes such as Tie2, CD34, CD31, 
CD144, and could uptake acetylated low-density lipo protein.  The hESC derived 
endothelial cells produced in this manor grew slowly and proved to be unstable and 
quickly were overrun by a secondary population of fibroblast or smooth muscle like 
cells [215].  This secondary non-EC population arose either from contaminating cells 
from the initial purification or from a trans differentiation process.   
Directed endothelial differentiation methods were established to eliminate 
these substantial stability problems.  Numerous groups found that addition of the 
cytokine BMP4 promoted EC differentiation.  Seminal work from Gordon Keller’s lab 
further defined the timing and development of hESC hematoendothelial 
differentiation [216].  Accordingly, they found adding mesoderm inducing signaling 
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cytokines BMP4 and activin A generated a primitive streak like population of cells 
that expressed brachyury (T).  With further time in culture these cells developed 
three distinct populations when analyzed by flow cytometry and gated on the 
expression of the vascular endothelial growth factor receptor 2 (VEGFR2) and c-KIT 
(KDR++c-KIT+, KDR+ c-KIT-, KDR-cKIT+).  Cardiac progenitors were found to be 
present in the KDR+ c-KIT- population and the hemangioblasts, precursor cells that 
can form blood cells or endothelial cells were present in the KDR++c-KIT+ population.  
Further stimulation with VEGF and FGF promoted this hemangioblast population into 
the endothelium, where as blocking WNT signaling pushed the KDR+ c-KIT- 
population into cardiomyocytes.  While this work established a mechanism for 
enriching in endothelial progenitors, the problems with EC stability remained.  This 
issue was recently solved through small molecule inhibition of TGF-β signaling [215].  
The expression of the endothelial specific markers CD144 and CD31 were present 
after isolation but so was expression of the smooth muscle marker α-SMA.  This 
indicated that purified cells retained plasticity to differentiate into terminal endothelial 
or smooth muscle cells.  TGF-β inhibition significantly blocked this transition and 
gave rise to a stable and pure population of ECs.  There was a seven-fold increase 
in the number of end point ECs when compared to the number of hESCs used to 
initiate the differentiation process.    
It is unlikely that CCM patient iPS cells will ever be used for regenerative or 
corrective cell transplantation due to the nature of disease development.  Most 
applications for regenerative medicine would be those for which cellular replacement 
would have a major effect such as diseases, which are due to a defective gene that 
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can be corrected through genome editing technologies or neurodegenerative 
diseases, which could benefit from replacement neurons.  The cell(s) of origin for 
CCM lesions is unknown; and therefore, it is impossible to replenish CCM proteins to 
all of the brain microvascular endothelial cells within a patient.  While the therapeutic 
treatment of CCM patients may not be an option with iPS cells, their in vitro 
theranostics potential is high. It is likely that a CCM patient library could help answer 
some of the outstanding questions in the CCM field.  First and foremost it will be 
important to establish whether patient cells have the same phenotype as observed in 
other CCM models.  Following this question it will become important to examine how 
the genetic penetrance of CCM patients affects disease onset, progression, and 
severity. iPS disease modeling could shed light into this area.  For example, the 
phenotypic severity of LQT2 patient derived iPS cells demonstrated milder 
phenotypes when obtained from asymptomatic patients when compared to severely 
symptomatic patients [217].  Most of the mouse models have indicated that 
homozygous loss of CCM proteins is required for lesion generation; however, at 
least one study has shown that heterozygous mice for CCM1 and CCM2 
demonstrated increased vascular leak [7].  Although it is widely thought that LOH is 
required for CCM lesion generation, it will be important to confirm this hypothesis in 
patient cells.  Most studies have concluded that CCM proteins act in an endothelial 
cell autonomous fashion; however, it is possible that there is a neural cell 
autonomous effects according to data obtained from mice lacking CCM3 in 
astrocytes [44].  Answering these basic signaling biological questions will be 
important for rationally designing therapeutics.  Small molecule drug discovery is an 
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additional unexploited avenue in the treatment of CCM.  It will be possible to 
differentiate ECs from patient iPS cells and use a small molecule library to identify 
compounds that reverse CCM relevant phenotypes, such as stress fiber formation, 
tight junction marker expression, hyper permeability, tube formation, or EC migration.  
Once a potential screened therapeutic or rationally designed therapeutic is tested for 
efficacy in reversing in vitro phenotypes, it will be possible to differentiate patient 
cells to hepatocytes and cardiomyocytes for in vitro toxicity testing of identified 
compounds.  Thus, CCM specific iPS cells represent a unique and novel way to 
address many outstanding questions in CCM biology with the eventual hope of 
developing new CCM patient specific therapeutics. 
This study investigated the potential for establishing a hiPS model of CCM.  
We show that hESCs remain pluripotent following shRNA mediated knock down of 
CCM1, -2, or -3 and can differentiate to endothelial cells.  We further show that 
endothelial progenitor cell derived ECs can model CCM, and be successfully 
reprogrammed to a pluripotent state.  These novel iPS cells can then be re-
differentiated to the endothelium.  Thus, our data suggests that CCM can be 
modeled using human pluripotent stem cells and warrants patient recruitment for 
patient cell reprogramming.    
 
Results: 
hESCs differentiate to the endothelium and can be used to model CCM phenotypes. 
hESCs are the gold standard for which all iPS cells are measured.  Thus, we 
elected to use hESCs to establish a method for differentiating pluripotent stem cells 
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to ECs and to determine whether pluripotent derived ECs recapitulate in vitro CCM 
phenotypes observed in heterologous EC cell types.  The simplest method for 
deriving endothelial cells was published following the random differentiation of EBs, 
which generated round 1-2% CD31+ cells, which could be further isolated by 
flourescence activated cell sorting (FACS) [214].  Accordingly, we generated EBs 
from H9 hESCs by scoring colonies into squares and gently lifting each section.  
After 24 hours, characteristically round EBs formed, and bFGF was removed to 
promote random non-directed differentiation (Fig 5.0 A).  EBs were allowed to 
differentiate for approximately 15 days, a time point where robust endothelial 
structures have been reported to form [214].  In contrast this previous reported 
differentiation result for H9 hESCs, we observed very little EC differentiation as 
reported by CD31 marker expression (Fig 5.0 B).  When these cells were isolated 
they failed to grow enough for validation studies.  These differences could be due to 
different methodologies for growing the hESCs or the health of the resultant EBs.  
This previously described method used LIF to grow hESCs, which is required for 
mESCs and has subsequently been shown to be dispensable for the maintenance of 
hESCs, and thus not included in our growth conditions.  Furthermore, we were 
unable to maintain EB cultures past 18 days due to senescence and cell death of the 
EBs without addition of differentiation inducing cytokines, and similar results were 
obtained for the H7 hESC line (data not shown). 
Non-directed differentiation was ineffective for two hESC lines, which have 
been reported to differentiate to ECs.  Therefore, we next examined whether hESCs 
would differentiate to ECs under a directed differentiation method.  A protocol was 
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recently developed, which initiates differentiation through transient mesoderm 
induction followed by endothelial specification and TGF-β inhibition [215, 216]. This 
differentiation method utilizes short-term EB growth followed by adherent plating 
conditions and EC isolation after 14 days (Fig 5.1 A). The mesodermal inducers 
BMP4 and activin A were added sequentially and were left on cells until day 4.  
Accordingly, addition of BMP4 increased expression of the mesodermal marker 
brachyury by day 3, where it rapidly decreased suggesting that these cells were 
specified into mesodermal lineages (Fig 5.1 B).  An increase in CD34, VEGFR2, 
cKIT, and VEcadherin protein levels were noticeable in a subset of differentiating 
cells by day 3, indicating that multi-potent vascular progenitors were forming (Fig 5.1 
C). At this point EBs were plated on adherent conditions and the vascular 
specification cytokine VEGF was added to the cultures along with BMP4 and bFGF.  
At day 7, the TGF-β inhibitor SB431542 was added to the cultures, and a noticeable 
increase in CD31 and VEcadherin (CDH5) mRNA levels were detected (Fig 5.1 B). 
VEcadherin protein expression was detected without CD31 protein detected 
suggesting that the cells were still in an immature state (Fig 5.1 C).  CD31 protein 
expression followed after approximately 14 days (Fig 5.1 D).  Putative ECs were 
isolated by FACs or through CD31 magnetic microbeads to at least 92% purity (Fig 
5.1 D).  These cells were able to grow in monolayers with VEcadherin expression at 
cell junctions, up take acetylated low density lipo protein, and form tube-like 
structures when plated on Matrigel demonstrating that this method of directed 
differentiation generates bone fide hESCs derived ECs (5.1 E). 
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Following isolation, ECs maintained endothelial characteristics but grew 
slowly. Therefore, we ascertained whether a better media could be formulated for 
the growth and expansion of hESC derived ECs.  A major driver of proliferation in 
ECs is the VEGF cytokine.  We titrated VEGF from two separate companies to 
determine if the slow growth kinetics of hESC derived ECs is due to low 
concentrations of VEGF.  Huvec proliferation was increased in a dose dependent 
fashion upon VEGF addition (Fig 5.2 A).  In contrast, hESC derived ECs remained 
constant at the maximal 100 ng/mL dose of VEGF from two separate vendors (Fig 
5.2 B).  This result suggests that hESC ECs are receiving adequate VEGF 
stimulation and are growing at their maximum growth rate under these conditions.  
Huvecs rapidly grow in EGM-2 commercial endothelial basal media, which contains 
EC specific growth factors.  Previous studies have suggested that hESC derived 
ECs proliferate better in EGM-2 media [218, 219].  Therefore, we examined the 
ability of our hESC derived ECs to proliferate in EGM-2.  We thus, grew our hESC 
derived ECs in EGM-2 media containing TGF-β inhibitor and noted a robust two fold 
increase in proliferation.  However, these ECs rapidly lost endothelial characteristics 
when grown in EGM-2 with delocalized VEcadherin and loss of tight junctions 
indicative of transition to a more mesenchymal phenotype (Fig 5.2 C).  We obtained 
similar results by removing serum from EGM-2 and replacing with knock out serum. 
While these growth conditions are significantly slower in hESC ECs, we empirically 
concluded that our vascular specification media supplemented with TGF- β inhibitor 
was the optimal growth media for the hESC derived ECs for future experimentation.  
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Following this protocol we have been able to consistently isolate hESC 
derived endothelial cells.  Therefore, we sought to determine if differentiation of 
hESCs lacking CCM1, -2, or -3 retained the ability to differentiate into endothelial 
cells.  Accordingly, H7 hESCs remained pluripotent with loss of CCM1, -2, or -3 by 
expression of the pluripotency marker Oct4 (Fig 5.3 A).  These cells differentiated 
into CD31+VEcadherin+ endothelial cells after 14 days (Fig 5.3 B). Over multiple 
experiments, the percentage of double positive cells was similar between control, 
CCM1, -2, and -3. (Fig 5.3 C).  Interestingly, during EB differentiation random 
sprouting of endothelial tube-like structures appeared in control cells but not in 
CCM2 deficient differentiating EBs when cultured on a thick layer of Matrigel (Fig 5.4 
A-C). These tube-like structures grew down into the Matrigel layer.  To better 
quantify potential tube formation defects, control, CCM1, -2, and -3 deficient ECs 
were isolated from differentiating H7 cultures.  After a transient expansion period, 
these cells were plated on Matrigel to assess endothelial specific tube formation 
differences in control and CCM deficient cells.  Control cells formed tube-like 
structures that had many nodes and branch points.  In contrast, loss of CCM1, -2, or 
-3 resulted in fragile tubes, which had fewer branch points and connections.  
Importantly, the defects in tube formation could be rescued with small molecule 
inhibition of the RhoA effector ROCK by either Y-27632, suggesting that RhoA 
signaling is defective in these ECs (Fig 5.5 A).  This result is consistent with results 
obtained in heterologous cell culture systems from multiple laboratories. Thus, H7 
derived ECs display phenotypic similarities with other endothelial cells lacking CCM 
proteins.  Therefore, we sought to further determine whether these effects were 
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through deregulated RhoA signaling and the actin cytoskeleton.  Accordingly, we 
detected an increase in total RhoA protein concomitant with an increase in 
phosphorylated cofilin (Fig 5.5 B).  Therefore, H7 derived ECs demonstrate elevated 
RhoA and a stabilized actin cytoskeleton. 
 
Isolation and characterization of endothelial progenitor derived endothelial cells as a 
model for CCM. 
These data suggest that pluripotent stem cells can be utilized to model CCM.  
Therefore, we decided to generate novel iPS cells generated from the endothelium 
that can model the CCM phenotype.  There is a growing body of evidence, which 
suggests that the somatic cell type of choice can influence the differentiation 
characteristics of the reprogrammed iPS cell [147, 169, 220-222]. These differences 
are attributable to an epigenetic memory effect.  Epigenetic memory is residual 
epigenetic gene expression marks left behind from the somatic cell of origin on the 
corresponding iPS cells.  Typically, these marks are strongest on genes that are 
important for cell identity or function.  Thus, in certain instances, iPS cells have been 
shown to preferentially differentiate back to the cell of origin over a different non-
related cell types.  Recently, the generation of iPS cells from endothelial cells has 
been described [223, 224].  Similar to other epithelial-like cells, these iPS cells 
appeared much faster than iPS cells derived from mesenchymal cells.  This result is 
likely because there is no requirement for a mesenchymal to epithelial transition 
[211].  Thus, our decision to utilize endothelial cells for iPS generation was for 
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increased efficiency of iPS cell generation coupled with the possibility for increased 
re-differentiation to the endothelium for the study of CCM phenotypes.  
Adult vascular cells require invasive surgery or punch biopsy techniques to 
obtain.  However, circulating endothelial progenitor cells (EPCs) have gained 
traction as a potential adult source of neovascularization and ECs [225, 226].  
Circulating EPCs can be obtained from the adult peripheral blood mononuclear cells 
(PBMC) after a simple non-invasive blood draw followed by ficoll density gradient 
centrifugation [227, 228].  These PBMCs can be frozen or shipped and retain 
functionality and viability.  Plating PBMCs on collagen IV in the presence of 
endothelial specific growth factors allows for early and late outgrowth EPCs to 
appear.  Accordingly, proliferative EPC derived endothelial cells (EPC-ECs) arise 
one to two weeks after plating.  They begin as small colonies of cells that we were 
able to obtain from 80 mL of peripheral blood with a success rate of 70% in healthy 
blood donors.  These EPC-ECs express VEcadherin, CD31, up take acetylated low 
density lipo protein (Ac-LDL), and generate tube-like structures when plated on 
Matrigel (Fig 5.6 A-D).  We did observe there was a difference in proliferative ability 
of EPC-ECs with some clones retaining proliferative ability beyond 5-7 passages 
and others prematurely senescing after 1-2 passages.  This broad variability is likely 
due to the age and number of cell divisions the circulating EPC had underwent in 
vivo before isolation and expansion in vitro. We next determined if these cells are 
able to model the CCM phenotype.  This information is important because they can 
be used as a stand-alone model for patient CCM phenotypes but more importantly 
because it is hypothesized that iPS cells generated from EPC-ECs will likely 
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redifferentiate to an EC, which is more similar to the original EPC-EC.  Following 
shRNA mediated knock down of CCM-1, -2, or -3, there was a marked decrease in 
tube-like structure formation rescuable by ROCK inhibition (Fig 5.7 A-C).  
Furthermore, two different isolations of EPC-ECs from patients demonstrated an 
increase in total RhoA protein, phospho-cofilin, and pMLC2.  These data indicate 
that EPC-ECs behave in a similar manner to hESC derived ECs, Huvecs, MEECs 
and bEND.3 endothelial cells and would be an amenable cell type for 
reprogramming (Fig 5.8) 
 
Generation of iPS cells from EPC derived ECs 
Therefore, we began by generating iPS cells from normal EPC-ECs.  IPS 
cells were also generated de novo from Huvecs and MRC5 fibroblasts for 
comparison.  The most efficient method for generating iPS is through the retro viral 
transduction of Oct4, Sox2, KLF4, and cMyc.  Individual PMX retroviral plasmids 
containing each transgene were transfected and virus was generated in 293T 
packaging cells.  EPC ECs, MRC5 fibroblasts, and Huvecs were all transduced with 
the same MOI viral titer. Each cell type was infected for 24 hours prior to being 
seeded on MEF feeder cells.  Huvecs and EPC ECs started forming iPS like 
colonies as early as 6 days after plating on the feeder layer and changing to iPS cell 
induction media with a much higher number of iPS like colonies (Fig 5.9). This result 
is in contrast to what was noted in MRC5 fibroblasts, which took much longer at over 
20 days.  These results are consistent with what has been previously published in 
Huvecs, which generate iPS cells quicker and at a higher efficiency than MRC5 
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fibroblasts [223].  Multiple clones from each line were subcloned and characterized 
for the establishment of successful reprogramming and pluripotency marker 
expression.  Accordingly, iPS clones from EPC-ECs, MRC5 fibroblasts, and Huvecs 
had high alkaline phosphatase activity, a functional marker for pluripotency (Fig 5.10 
A).  In addition, the iPS clones from all cells activated the core pluripotency 
transcriptional network as evidenced by immunoflourescent imaging and qRT-PCR 
expression of Oct4, Sox2, and Nanog (Fig 5.10 A and B).  To rule out that Oct4 and 
Sox2 expression was due to residual transgene expression, we designed q-RT-PCR 
primers that were selective for the 5’ UTR region of the virus. The resulting 
expression data showed that transgene expression was high in OSKM infected 
EPC-ECs but was efficiently silenced in all stable iPS clones (Fig 5.10 C).  Retroviral 
gene silencing is a hallmark of successful reprogramming [159].  Other markers of 
pluripotency TDGF1 and Nodal were highly expressed; interestingly a higher 
expression of Nodal was detected in 3 out of 4 EPC-EC iPS clonal lines (Fig 5.10 B).  
The consequences of this expression difference were not investigated and are 
unknown.  Thus, iPS cells generated from huvecs and EPC-ECs reprogram faster 
and express pluripotency markers at levels equivalent to hESCs and MRC5 
fibroblast derived iPS cells. 
We next determined the differentiation potential of our EPC-EC derived iPS 
cells.  In vitro there are two methods for establishing pluripotency: random and 
directed differentiation of EBs.  To establish whether our EPC-EC clones could 
differentiate into all germ layers, a hallmark of pluripotency, we generated EBs and 
differentiated the cells in non adherent conditions for 14 days in hESC basal media 
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without bFGF.  EBs were then stained for SMA, AFP, and Nestin (neural progenitor) 
as well as MAP2 (neuron) markers of the mesoderm, endoderm, and ectoderm 
respectively (Fig 5.11 A).  In a subset of EBs we detected expression of each of 
these markers, indicating that EPC-EC iPS cells are pluripotent and are capable of 
in vitro differentiating to each of the three germ layers (Fig 5.11 A).  In addition to 
random EB mediated differentiation, we sought to determine whether our EPC-ECs 
could be directed to differentiate into different tissues. Utilizing different cytokine 
inducers, we were able to drive our EPC-EC iPS lines into Nestin+ neural progenitors, 
TuJ1+ neurons, GFAP+ astrocytes (Fig 5.11 B). Importantly, we were able to 
generate CDH5/LDL uptake positive ECs (Fig 5.11 C).  These results demonstrate 
that both random and directed differentiation of EPC-EC iPS cells is possible.  The 
most stringent available assay for pluripotency of human iPS cells is teratoma 
formation. Teratomas are embryonic tumors, which consist of many different body 
tissues that originate from the three germ layers.  Following injection in the flank of 
Nude mice, teratoma formation occurred after approximately four weeks with 5 out of 
6 injected animals forming tumors.  Upon histological analysis, each teratoma 
displayed tissue structures retinal-pigmented epithelium, ciliated enterocytes, and 
chondrocytes from the ectoderm, endoderm, and mesoderm, respectively (Fig 5.11 
D).  Thus, these characterizing studies demonstrate that we were able to generate 
iPS cells from a completely novel cell type (denoted now as epiPS). 
We next to investigated the differentiation potential of huvec and epiPS to 
endothelium and whether the proposed epigenetic memory mechanism promotes 
the differentiation to endothelial cells.  We utilized the same differentiation protocol 
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as we had established for the differentiation of hESCs to ECs to differentiate the 
huvec, and epiPS cells to endothelium.  Interestingly, we found that the 
differentiation kinetics of the EC derived iPS cell lines (Huvecs iPS and epiPS) 
differed from hESCs.  There was a greatly enhanced induction of VEcadherin 
expression that persisted for up to 20 days followed by an increase a progressive 
and slower increase in CD31 (Fig 5.12). Microbead isolation of epiPS derived ECs 
showed that these cells express the endothelial specific markers VEcadherin, CD31, 
and were capable of acetylated LDL uptake (Fig 5.11 C) however, the total number 
of epiPS-ECs cwas comparable to H7 hESCs.  These data suggest that epiPS cells 
can generate ECs.  The epigenetic memory effect is restricted to VEcadherin, which 
is expressed on other cells other than ECs.  Therefore, we observed an epigenetic 
memory on one endothelial marker but this did not enhance EC derivation from 
epiPS.  Further investigation into the differentiation kinetics of epiPS may yield better 
EC yields.  Perhaps following a similar differentiation kinetic that EPCs follow to 
generate EPC-ECs will be more applicable to the differentiation of epiPS to the 
endothelium.   
 
Discussion: 
These studies demonstrate that hESC derived ECs can be used for the study 
of CCM.  The cell phenotypes that other groups have observed in heterologous EC 
systems from both mouse and human are conserved with hESCs.  We have also 
demonstrated that CCM regulates RhoA levels and downstream signaling in hESC 
derived ECs.  hESCs undergo apoptosis when in single cell conditions due to over 
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activation of the RhoA/ROCK pathway.  Our knock down hESC lines were 
completely healthy and maintained equal growth rates compared to control lines 
even when split at sparse ratios.  These observations were confirmed, as there was 
no deregulation of RhoA/ROCK signaling in hESCs by phospho-cofilin or pMLC2 
immunoblotting.  These data demonstrate for the first time that loss of CCM proteins 
effect angiogenesis and not the endothelial differentiation of human cells, which is 
consistent with what has been observed from multiple mouse models.  Using hESCs 
has demonstrated that the development of a patient specific iPS cell model is 
possible, and more broadly, this is the first data that has attempted to model an 
endothelial specific disease in pluripotent stem cells.  
It is important to consider multiple cell types when deriving iPS cells from 
patients.  Fibroblasts and keratinocytes are well proven, but are invasive to obtain.  
Blood represents a minimally invasive and easily obtained source of cells from which 
iPS cells can be generated from relatively small amounts.  Using this logic, we were 
able to generate peripheral blood EPC derived ECs.  These cells demonstrated 
robust phenotypes after shRNA knock down of the CCM proteins.  More importantly, 
these cells rapidly generated high quality iPS clones that demonstrate all of the 
hallmarks of pluripotent hESCs. These epiPS cells are capable of differentiating 
along the three germ layers and form endothelial cells.  Unexpectedly, these cells 
only retained an epigenetic memory of VEcadherin expression, which is not as 
specific an endothelial marker as CD31 or Tie2 and did not display any enhanced 
differentiation kinetics to the endothelium when compared to hESCs. Further work 
may need to be done to fully demonstrate CCM phenotypes following shRNA knock 
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down of the CCM proteins in epiPS cells, but these validation studies suggest that 
EPCs can be utilized to generate iPS cells for the study of CCM.  Other peripheral 
blood cells, including erthyroblasts can be used to obtain iPS cells from as little as 
10 mL and are actively being tested in the laboratory.  Thus, this study has overall 
demonstrated the generation of iPS cells from a novel cell source and that making 
patient specific iPS cells to model CCM is feasible
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Figure 5.0:  H9 hESCs do not randomly differentiate efficiently to CD31+ ECs. 
A).  Images showing the scoring of healthy H9 hESCs for EB formation at D0.  D2 
and D10 images are of EBs grown in adherent conditions without bFGF, and D14 
image shows the formation of fully differentiated cystic embryoid bodies.  B).  Flow 
cytometry analysis demonstrates a less than .1% differentiation efficiency of H9 
hESCs compared to fully differentiated Huvecs, which are 95% positive for the 
endothelial specific marker CD31 (PECAM1)   
	  
	  
140	  
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1:  Mesodermal inducing cytokines followed by TGF-β inhibition 
promote H7 hESC differentiation to CD31+CDH5+ ECs. A).  Differentiation 
timeline protocol.  B).  qRT-PCR analysis of the vascular markers Pecam1 (CD31) 
and CDH5 (VEcadherin), the pluripotency marker Oct4, and the early mesoderm 
marker Brachyury.  C).  Flow cytometry analysis of H7 hESC differentiating EBs.  D).  
Flow cytometry analysis of differentiating EBs pre and post CD31 bead isolation. E).  
Isolated ECs express VEcadherin and uptake acetylated low-density lipoprotein (left 
panel 40x objective) and form tube-like structures (right panel 10x objective) 
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Figure 5.2:  hESC derived ECs grow best in the vascular specification media.  
A).  Dose-dependent Proliferation of Huvecs following VEGF stimulation, indicating 
that the VEGF used in this study is functional.  B). Proliferation profile of Huvecs and 
H7 derived ECs in vascular specification media with two different forms of VEGF or 
grown in EGM-2, demonstrating that proliferation is increased in EGM-2 media with 
no differences in VEGF vendor source.  C).  Immunoflourescent imaging of H7 ECs 
or Huvecs grown in different media formulations.  Cells grown in two different 
sources of VEGF were identical; where as, H7 ECs grown in EGM-2 lost endothelial 
characteristics. Images were taken at 10X magnification for monolayer visualization.        
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Figure 5.3:  CCM protein knock down does not affect hESC pluripotency or 
differentiation to the endothelium.  A). qRT-PCR analysis demonstrating that 
CCM proteins are effectively silenced by specific shRNAs in hESCs, and loss of 
CCM proteins does not effect the expression of the pluripotency marker Oct4.  B).  
Representative flow cytometry plot demonstrating that CCM protein deficient knock 
hESCs are able to differentiate to Pecam1+VEcadherin+ ECs.  C).  Quantification of 
multiple experiments, showing that CCM protein knock down does not significantly 
effect endothelial differentiation (n=4 experiments).   
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Figure 5.4:  WT but not CCM knock down EBs sprout tube-like structures from 
differentiating EBs.  A).  WT differentiating EBs seeded on Matrigel send out 
multiple sprouts from EBs, indicating that active angiogenesis is occurring in these 
cultures.  B).  CCM2 (OSM) stable knock down differentiating EBs are smaller and 
demonstrate high levels of migration but no tube-like structurers form.  C).  Higher 
magnification (20X objective) of panel A (10X objective).    
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Figure 5.5:  CCM proteins regulate endothelial function through RhoA in hESC 
derived ECs.   A).  shPlko.1 control ECs generate tube-like structures where as 
CCM1, -2, or -3 knock down cells are deficient in their ability to form tubes.  These 
phenotypes are rescued by treatment with 10 µM Y-27632  B). ECs derived from 
hESCs with stable CCM protein knock down demonstrate elevated RhoA levels and 
pCofilin, suggesting that the phenotypes detected are due to deregulated RhoA 
signaling.  C).  hESCs do not have deregulated RhoA levels or elevated pCofilin, 
suggesting that RhoA is not deregulated in the pluripotent parental stem cell with 
CCM protein loss. 
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Figure 5.6:  Endothelial progenitor cell derived ECs can be derived from 
peripheral blood.   A).  Peripheral blood is drawn from patients, spun on a ficoll 
gradient, the PBMCs are isolated and then plated on collagen IV.  B).  Late out 
growth endothelial progenitor cells start forming small colonies around 6 days and 
continue to grow.  C).  These EPC-ECs express high levels of Pecam-1, 
VEcadherin, and CD34.  D).  EPC-ECs form tight juntions with VEcadherin (CDH5) 
expressed at the membrane and are capable of uptaking acetylated low density lipo 
protein.  EPC-ECs also form tube-like structures when plated on Matrigel.       
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Figure 5.7:  CCM1, -2, and -3 deficient endothelial progenitor cells are unable 
to form tube-like structures A).  Knock down of CCM proteins abrogates proper 
tube formation ability in EPC-ECs, which is rescuable with ROCK inhibition.  B). 
Quantification of tube formation assays from multiple independent experiments (*P= 
< .05).  C).  qRT-PCR validation of mRNA knock down in EPC-ECs.     
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Figure 5.8:  Two independent sources of EPC-ECs demonstrate elevated RhoA 
signaling.  RhoA, pMLC2, and pCofilin are all increased in CCM protein deficient 
EPC-ECs indicating that RhoA and its downstream effectors are over activated.  
Right panels are the quantifications from multiple western blots (*P= < .05).  
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Figure 5.9:  EPC-ECs form iPS colonies after retroviral transduction with Oct4, 
Sox2, Klf4, and cMyc.  A).  iPS reprogramming timeline used for the generation of 
all iPS clones.  B). EPC-ECs were transduced at approximately 50% as estimated 
by GFP expression.  Mature colonies started forming as little as 6 days after 
transduction; panel below shows an example of partially reprogrammed colonies. 
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Figure 5.10:  EPC-EC derived iPS cells express a panel of pluripotent stem cell 
markers.  A).  Reprogrammed EPC-ECs express pluripotency markers by 
immunoflourescence.  B).  qRT-PCR analysis shows that EPC-EC iPS cells express 
pluripotency markers to levels comparable to H7 hESCs.  C).  EPC-EC iPS cells 
have shut down the expression of Oct4, Sox2, KLF4, and cMyc transgenes.   
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Figure 5.11:  EPC-EC derived iPS cells are able to differentiate to all three 
germ layers A).  EPC-EC iPS cells are able to differentiate to the mesoderm 
(smooth muscle actin; SMA), endoderm (alpha fetoprotein; AFP), and ectoderm 
(nestin and Map2) germ layer tissues by immunoflourescence.  B). EPC-EC iPS 
cells can be cytokine directed to differentiate to neural rosette structures which 
contain Nestin+ neural progenitors, TuJ1+ neurons, or GFAP+ astrocyctes.  C).  EPC-
EC iPS cells can be re-differentiated back to ECs that express CDH5 (VEcadherin) 
and can uptake AC-LDL.  D).  EPC-EC iPS cells form teratomas in vivo, which form 
endodermal tissues (left panel; ciliated enterocytes), ectodermal tissues (middle 
panel; pigmented retinal epithelium), and mesodermal tissues (right panel; immature 
cartilage).   
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Figure 5.12:  Endothelial derived iPS cells have enhanced VEcadherin 
expression during differentiation A).  Flow cytometry analysis of VEcadherin 
expression in H7 hESC, epiPS, and Huvec iPS differentiating cultures.  VEcadherin 
expression was greatly increased after 14 days of differentiation when compared to 
hESC control lines.    
 
 
 
 
 
 
VI.  Concluding remarks 
Summary 
CCM is a relatively common blood vascular disease, which has broad 
phenotypic and psychological effects.  In many aspects CCM is similar to tumor 
formation as CCM lesions may form randomly and effect people, which have no 
genetic predisposition for the disease.  CCM lesions can be both completely 
physically disabling, but perhaps equally psychologically damaging; patients neither 
know when a lesion may hemorrhage nor when they may become disabled.  There 
is no cure, and the options for treatment is limited to invasive surgery.  Thus, the 
goal of the collective CCM field is to develop new pharmacological treatment options 
for CCM patients, which both inhibits lesion genesis and recesses current lesions.  
To address this challenge, this body of work has attempted to further define the 
CCM signaling network and establish whether CCM patient specific pluripotent stem 
cell disease modeling is possible. 
To date, there are no known prior studies investigating the involvement of the 
kinome in CCM.  Kinases are the major class of proteins that integrate extracellular 
signaling cues to cellular responses, and represent a vastly understudied component 
of CCM.  Indeed, the effects of RhoA and ROCK in driving CCM phenotypes are well 
described and represent an important therapeutic strategy for the pharmacological 
treatment of CCM.  However, there may be a wealth of other potential targetable 
kinases driving the CCM disease process.  Thus, to investigate this greatly 
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understudied aspect of CCM, we utilized MIB/MS, a novel technology that identifies 
unknown kinases in a completely unbiased manner.  Our analysis showed that we 
were able to detect approximately 30% of the known kinome in our ECs.  Many of 
these kinases were changed following the loss of the CCM proteins, many of which 
directly regulate the actin cytoskeleton.  Moreover, many of the upregulated kinases 
have small molecule inhibitors available and were common between CCM1, -2, and 
-3 deficient ECs.  We validated LIMK1 from our kinome profiling as being overactive 
and a major driver of a stabilized actin cytoskeleton downstream of RhoA and ROCK.  
Inhibition of LIMK1 by specific shRNAs rescued CCM phenotypes to the same 
extent as upstream ROCK inhibition.  This finding is highly relevant to CCM as this 
kinase has cofilin as its one known substrate.  The only other pharmacological 
avenues currently available for CCM are direct RhoA inhibition with Simvastatin or 
ROCK inhibition with hydroxyfasudil.  RhoA and ROCK carry out a myriad of 
functions, and inhibiting them would be intrinsically less specific than an approach 
targeting LIMK1.  Inhibitors of LIMK1 are currently being developed, and the effect of 
these inhibitors in vivo will be important to establish whether lesion recession is 
equal to that of hydroxyfasudil administration.  The overall data generated from 
these kinome studies will be a resource for the CCM field to interrogate novel kinase 
networks involved in CCM, which may contribute to the development of new 
therapeutic strategies. 
In addition to interrogating kinome networks in CCM, we have further 
established the role of deregulated degradation of the small GTPase RhoA as a 
molecular mechanism driving CCM phenotypes.  These data suggest that the CCM 
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protein complex promotes Smurf1 ubiquitination of GTP bound RhoA in ECs, which 
is required for normal endothelial function.  Increased GTP bound RhoA is found in 
numerous pathological conditions and ubiquitin modification is an emerging theme in 
the regulation of small GTPases.  Thus, more broadly this work demonstrates for the 
first time that decreased ubiquitination of GTP bound RhoA contributes to the 
molecular biology behind a genetic disease and may represent a new paradigm 
when thinking about diseases affected by deregulated GTPase activity.   
It is critical to study diseased cells from CCM patients to determine whether 
these in vitro and in vivo model phenotypes are relevant with the complex genetics 
of CCM patients.  To begin to address this need, we developed a hESC model 
system of CCM to validate the feasibility of modeling diseased patient ECs from iPS 
cells.  Accordingly, we found that hESCs remain pluripotent following CCM protein 
loss, and differentiated ECs demonstrate in vitro CCM phenotypes.  We further 
demonstrated that EPC-ECs can be generated from normal healthy donors, and 
these cells also can be used to model CCM phenotypes following shRNA knock 
down of the CCM1, -2, and -3.  Lastly, we showed that iPS cells can be successfully 
generated from these EPC-ECs and can be re-differentiated to the endothelium for 
CCM disease modeling.  These data importantly demonstrate the feasibility of 
pluripotent stem cell disease modeling of CCM.  Thus, a library of CCM patient iPS 
cells will allow the study of CCM in a patient specific way and may aid in elucidating 
the molecular mechanistic differences between CCM1, -2, and-3 patients. 
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Future Directions 
Many challenges and outstanding basic research questions still face the CCM 
field.  There is a great unmet need for treatment options for CCM patients, and it is 
important to remain focused on first answering those questions that will lead to the 
development of a feasible pharmacological strategy for the treatment of CCM.  
Broad genomic and proteomic approaches carried out in actual diseased CCM cells 
are paramount to understanding the relevant molecular mechanisms behind CCM 
pathology.  The elucidation of at least one of these pathways has already led to the 
first clinical trial in CCM with Simvastatin.  While this news is encouraging, more 
options are needed and collaborations between clinicians, basic research scientists, 
and patient advocacy groups will greatly increase the speed at which CCM biology is 
understood and new therapeutics generated. 
Through our kinome profiling studies, we provide the first information into the 
global deregulation of kinase signaling in CCM deficient ECs.  These data will be 
best used in concert with other broad discovery based technologies.  For example, 
RNA sequencing of CCM deficient cells coupled with these kinome profiling studies 
will allow for the identification of gene signature changes that may be driving 
important previously unknown cellular changes.  A major goal of the Angioma 
Alliance CCM patient advocacy group is to collect blood samples for genomic 
sequencing and tissue lesion samples for basic research.  In the future, proteomic 
studies coupled with RNA and whole genome sequencing from patients will allow for 
the identification of protein and transcription networks deregulated in CCM and the 
baseline genomic mutations that may underlie these aberrant networks.  Thus, a 
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more accurate picture of what is happening at transcriptional, genomic, and 
proteomic levels will serve as a resource for the CCM community to drive new 
hypotheses of pathways currently not recognized as being important in CCM biology.   
 There is a consensus in the field that deregulated RhoA signaling contributes 
to an aberrant cytoskeletal state in CCM deficient ECs, which gives rise to CCM 
phenotypes.  Understanding how the cytoskeleton is regulated in ECs may provide 
immediate therapeutic avenues.  We describe the importance of the CCM proteins in 
coordinating Smurf1 and Smurf2 regulation of RhoA and Rap1, respectively.  RhoA 
is thought to antagonize Rap1 function by increasing monolayer permeability.  
Therefore, further understanding the interplay of these two small GTPases and 
potentially increasing Rap1 activity over RhoA may represent a new therapeutic 
avenue for CCM.   
 Many fascinating basic science questions remain unanswered.  Perhaps the 
most difficult question to answer is how lesions initially form.  Genomic instability 
seems to be an obvious answer; however, CCM patients do not have increased 
rates of cancer through genomic mutations.  What makes the ccm gene loci so 
predisposed for genetic mutations; what is the selective pressure for these 
mutations?  The CCM cell of origin may shed light into this question, especially if 
there is a defective circulating endothelial progenitor cell or other stem cell, which 
can hone to sites of active angiogenesis and contribute to CCM lesion formation.   
In addition to the genetics of CCM, many questions remain into where and 
how the CCM proteins function.  Our lab demonstrated that the CCM proteins are in 
complex with each other.  What is the stoichiometry of this complex; when during the 
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many complex functions of an EC do these proteins interact?  Undoubtedly 
endogenous fluorescent or epitope tagging approaches coupled with live cell high-
resolution microscopy will help answer these questions.  Along these lines, this 
thesis provides proof of concept studies using hESCs and hiPS cells as a first step 
to developing these tools to answer these types of questions.  Thus, these cells can 
be used for both the study of disease patient cells and targeted with next generation 
gene targeting strategies for endogenous protein tagging.  Overall, research in the 
CCM field is moving at a rapid pace with many novel avenues of research from the 
constant growth of new CCM researchers, and work in the near future will couple 
these basic science discoveries to the development of a novel therapeutic for CCM 
patients. 
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